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1. INTRODUCTION 
TABLETS 
HISTORICAL BACKGROUND 
  Oral route is a most common route of administration; about 90 percent of 
drugs are administered via oral route for systemic effects. Among the drugs administered 
orally, solid dosage forms represent the preferred choice of class of product. Most 
common solid oral dosage forms are tablets and capsules. Tablets and capsules account for 
well over half the total number and cost of all prescription issued. In December 1843, a 
patent was granted to the Englishman, William Brockedon, for a machine to compress 
powders to form compacts. The invention was first used to produce compacts of potassium 
bicarbonate and caught the imagination of a number of pharmaceutical companies. Later, 
Wellcome, in Britain was the first company to use the term tablets to describe the 
compressed dosage forms. 1  
What is tablet? 
  Tablets are solid preparations each containing a single dose of one or more 
active medicaments and usually obtained by compressing uniform volumes of particles. 
Tablets are intended for oral administration. Some are swallowed whole or after being 
chewed, some are dissolved or dispersed in water before being administered and some are 
retained in the mouth where the active medicament is liberated. Tablets are usually solid, 
right circular cylinders, the end of which are flat or convex and the edges of which may be 
bevelled.  They may exist in other shapes like triangular, rectangular, etc. They may have 
lines or break-marks and may bear a symbol or other markings. Tablets may be coated or 
uncoated. They are sufficiently hard to withstand handling without crumbling or 
breaking.2 
The British Pharmacopoeia defines tablet as, circular in shape with either  flat or 
convex faces and prepared  by compressing the medicament or mixture of medicaments 
usually with the added excipients, such as diluents, binders, disintegrants, glidants, 
lubricants, substance capable of modifying the preparation in the digestive tract, colouring 
matter authorised by the competent authority and flavouring substances. 
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ADVANTAGES OF TABLET MEDICATION 3 
 They are the unit dosage form and offer the greatest capabilities of all oral dosage 
forms for the greatest dose precision and least content variability. 
 Low cost of among all oral dosage forms. 
 They are lightest and most compact dosage forms. 
 They are easiest and cheapest to package and ship. 
 Product identification requires no additional processing steps when employing an 
embossed or monogrammed punch face. 
 Provides greatest ease of swallowing with the least tendency for hang up above the 
stomach, especially when coated, provided the tablet disintegration is not excessively 
rapid. 
 They lend themselves to certain special release profile products e.g. enteric coated or 
delayed release profiles. 
 Easy large scale production than other oral dosage forms. 
 They have the best combined properties of chemical, mechanical and microbiological 
stability among all the oral dosage forms. 
 The emergency supplies of the drug can be conveniently carried by the patient. 
 
DISADVANTAGES OF TABLET MEDICATION 3 
 Some drugs have resistance for compression into dense compacts, owing to their 
amorphous nature or flocculent, low density properties. 
 Drugs with bitter taste, objectionable odour, sensitivity towards oxygen or 
hygroscopic nature may require encapsulation/entrapment prior to compression, or 
coating of tablets is required. 
 Elderly, ill and children could have problem in swallowing the tablets. 
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TYPES OF TABLETS 4 
                        Tablets are divided into classes based on their route of administration and 
their function.  
1. TABLETS ADMINISTERED ORALLY 
A. Compressed tablets 
• Sugar coated tablets 
• Film coated tablets 
• Enteric coated tablets 
• Chewable tablets 
• Controlled release tablets 
B. Multiple Compressed Tablets 
• Layered tablets 
• Press coated tablets 
2. TABLETS ADMINISTERED IN ORAL CAVITY 
A. Buccal and sublingual tablets 
B. Lozenges and Troches 
C. Dental cones 
3. TABLETS ADMINISTERED VIA OTHER ROUTES 
A. Implants 
B. Compressed suppositories or inserts 
4. TABLETS ADMINISTERED IN SOLUTION FORM 
A. Effervescent tablets 
B. Dispensing tablets 
C. Hypodermic tablets 
D. Tablet triturates 
METHOD OF PREPRATION OF GRANULES FOR TABLETS 4 
1. Wet granulation  
2. Dry granulation 
3. Direct compression 
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FLOWCHART FOR DIFFERENT METHODS FOR TABLET GRANULATION 
PREPARATION 
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MULTILAYER TABLETS 5 
                
  Multilayer tablets are tablets made by compressing several different granulations 
fed into a die in succession, one on top of another, in layers. Each layer comes from a 
separate feed frame with individual weight control. Rotary tablet presses can be set up for 
two or three layers. More are possible but the design becomes very special. Ideally, a 
slight compression of each layer and individual layer ejection permits weight checking for 
control purposes. 
 
Advantages of Multilayer Tablets 
1. Incompatible substances can be separated by formulating them in separate layers as a 
 two-layer tablet or separating the two layers by a third layer of an inert substance as a 
 barrier between the two. 
2. Two layer tablets may be designed for sustained release; one layer for immediate
 release of the drug and the second layer for extended release, thus maintaining a 
 prolonged blood level. 
3. Layers may be coloured differently to identify the product. 
 
VARIOUS TECHNIQUES FOR A BILAYER TABLET 6  
            The techniques are as follows 
01. OROS® push pull technology 
02. L-OROS tm technology 
03. EN SO TROL technology 
04. DUROS technology 
05. DUREDAS™ technology 
 
01. OROS® push pull technology 
    This system consists of mainly two or three layers which among one or more 
layer are essential of the drug and other layer consist of push layer. The drug layer mainly 
consists of drug along with two or more different ingredients. The drug layer consists of 
poorly soluble drug. There is further addition of suspending agent and osmotic agent. A 
semi permeable layer surrounds the tablet core. 
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Fig. 1: Bilayer and Trilayer OROS push pull technology 
 
02. L-OROS tm technology 
   This system used for the solubility issue. Alza developed the L-OROS system 
where a lipid soft gel product containing drug in a dissolved state is initially manufactured 
and then coated with a barrier membrane, then with a osmotic push layer and then a semi 
permeable layer membrane drilled with an external orifice.  
 
 
Fig. 2: L-OROS tm technology 
 
03. EN SO TROL technology 
   Solubility enhancement of an order of magnitude or to create optimized 
dosage form Shire laboratory used an integrated approach to drug delivery focusing on 
identification and incorporation of the polymer that enhances the controlled release 
technologies. 
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Fig. 3: EN SO TROL technology 
 
04. DUROS technology 
            The system consists of an outer cylindrical titanium alloy reservoir. The 
reservoir has high impact strength and protects the drug molecules from enzymes. The 
DUROS technology is the miniature drug dispensing system that opposes like a miniature 
syringe and release minute quantity of concentrated form in continuous and consistent 
form over months or years.  
  
Fig. 4:  DUROS technology 
 
 
05. DUREDAS™ technology 
   It is a bilayer tablet which can provide immediate or sustained release of two 
drugs or different release rate of the same drug in one dosage form. The tabletting process 
can provide an immediate release granulate and a modified- release hydrophilic matrix 
complex as separate layers within the one tablet. The modified-release properties of the 
dosage form are provided by a combination of hydrophilic polymers.  
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Fig. 5: DUREDAS Technology 
 
Benefits offered by the DUREDAS™ technology includes: 
 Bilayer tabletting technology. 
 Tailored release rate of two drug components, 
 Capability of two different CR formulations combined. 
 Capability for immediate release and modified release components in one 
tablet. 
 Unit dose, tablet presentation 
 
   The DUREDAS™ system can be easily manipulated to allow incorporation 
of two controlled release formulation in the bilayer. Two different release rates can be 
achieved from each side.  In this way greater prolongation of sustained release can be 
achieved. Typically an immediate release granule is compressed first followed by the 
addition of a controlled release element which is compressed onto the initial tablet. This 
gives the characteristic bilayer effect to the final dosage form. 
   
                A further extension of DUREDAS™ technology is the production of 
controlled release dosage forms where by two drugs are incorporated into the different 
layers and drug release of each is controlled to maximise the therapeutic effect of the 
combination. Again both immediate and controlled release combinations of two drugs are 
possible. 
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PRECAUTIONS TO BE TAKEN TO GET GOOD BILAYER TABLETS 5   
          For good-quality tablets with sharp definition between the layers, special care 
must be taken as follows: 
1. Dusty fines must be limited. Fines smaller than 100 mesh should be kept at a minimum. 
2. Maximum granule size should be less than 16 mesh for a smooth, uniform scrape-off at 
 the die. 
3. Materials that smear, chalk, or coat on the die table must be avoided to obtain clean 
 scrape-off and uncontaminated layers. 
4. Low moisture is essential if incompatibles are used. 
5. Weak granules that break down easily must be avoided. Excessive amounts of 
 lubrication especially metallic stearates should be avoided for better adhesion of the 
 layers. 
6. Formulation of multilayer tablets is more demanding than that of single layer tablets. 
  For this reason, selection of additives is critical. 
 
IMMEDIATE RELEASE TABLETS 
 
   Immediate release dosage forms are those for which ≥ 85% of the labelled 
amount dissolves within in 30 minutes. For immediate release tablets, the only barrier to 
drug release is simple disintegration or erosion stage which is generally accomplished in 
less than one hour. To enhance dissolution and hence bioavailability of any drug for 
immediate release tablets, disintegration is one of the important process.7  Disintegrants are 
substances or mixture of substances added to the drug formulation that facilitates the 
breakup or disintegration of tablets or capsule content into smaller particles that dissolves 
more rapidly than in the absence of disintegrants. Superdisintegrants are generally used at 
a low level in the solid dosage form, typically 1-10% by weight relative to the total weight 
of the dosage unit. Few superdisintegrants are available commercially as Croscaramellose 
sodium, Crospovidone and Sodium starch glycolate.  
  Tablets for immediate release often consist of filler, a binder, lubricants and 
disintegrants. In many cases, the disintegration time of solid dosage forms is too long to 
provide appropriate therapeutic effect. To improve the disintegration time, so-called 
disintegrants are used. The most accepted mechanisms of their action are wicking, 
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swelling, and deformation recovery and particle repulsion.8 Together, these phenomena 
create a disintegrating force within the matrix. In the past, non-modified disintegrants 
were used to accelerate disintegration, that is, alginates, starches, ambrelite resins, 
cellulosic materials, pectines and others. Today, a fast working superdisintegrant is 
chemically modified, typically by cross linking the organic chains of a polymeric 
molecule. Three classes of superdisintegrants are commonly used. Modified cellulose 
(Croscaramellose Sodium - Ac-Di-Sol®, Vivasol®), crosslinked polyvinyl-l pyrrolidone 
(Polyplasdone® XL-10) and modified starch (Sodium Starch Glycolate – Primojel®, 
Explotab®) 
 
CONTROLLED DRUG DELIVERY SYSTEMS 9 
   In the past, many of the terms used to refer to therapeutic systems of 
controlled and sustained release have used in an inconsistent and confusing manner. 
Although descriptive terms such as “timed release” and “prolonged release” give excellent 
manufacturing identification, they can be confusing to health care practitioners. 
                      
  Sustained release constitutes any dosage form that provides medication over 
an extended period of time. Controlled release however denotes that the system is able to 
provide some actual therapeutic control, whether this is of temporal nature, spatial nature or 
both. In other words, the system attempts to control drug concentrations in the target tissue. 
This correctly suggests that there are sustained release systems that cannot be considered as a 
controlled release systems. 
 
 In general, the goal of a sustained release dosage form is to maintain 
therapeutic blood or tissue levels of the drug for an extended period. This is usually 
accomplished by attempting to obtain zero order release from the dosage form. Zero order 
release constitutes drug release from the dosage form that is independent of the amount of the 
drug in the delivery system (i.e., a constant release rate). 
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                          Sustained release generally do not attain this type of release and usually 
try to mimic zero order release providing drug in a slow first order fashion (i.e., 
concentration dependent). 
 
                        Systems that are designated as prolonged release can be considered as 
attempts at achieving sustained release delivery. Repeat action tablets are a method of 
sustained release in which multiple doses of a drug are contained within the dosage form 
and each dose is released at a periodic interval. Delayed release systems, in contrast, may 
not be sustaining, since often the function of these dosage forms is to maintain the drug 
within the dosage form for some time before release. Commonly the release rate is not 
altered and does not result in sustained delivery once drug release has begun. Enteric 
coated tablets are example of this type of dosage form. 
                        
     Controlled release, although resulting in a zero order delivery system, may 
also incorporate methods to promote localization of the drug at an active site. In some 
cases, a controlled release system will not be sustaining, but will be concerned strictly 
with localization of the drug. Site- specific systems and targeted delivery systems are the 
descriptive terms used to denote this type of delivery control. 
 
GENERAL PRINCIPLE OF CONTROLLED RELEASE SYSTEMS 
 
                             The idea of providing an exact amount of drug at the site of action for a 
precise time period is usually approximated by most systems. This approximation is 
achieved by creating a constant concentration in the body or an organ over an extended 
period of time; in other words, the amount of drug entering the system is equivalent to the 
amount removed from the system. All forms of metabolism and excretion are included in 
the removal process: urinary excretion, entero hepatic recycling, sweats, faecal and so on. 
Since for most of the drugs these elimination processes are first order, it can be said that at 
certain blood level, the drug will have specific rate of elimination. This idea is to deliver 
drug at the exact rate for an extended period. This is represented mathematically as 
 
Rate in = Rate out = Kelim X Cd X Vd 
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  Where, Cd is the desired drug level, Vd is the volume of distribution and Kelim 
is the rate of drug elimination from the body. Often such exacting delivery proves to be 
difficult to achieve administration routes other than intravenous infusion. Non invasive 
routes (e.g., oral) are obviously preferred. 
 
 
Fig. 6: Drug level versus time profile showing differences between zero order controlled 
release, slow first order sustained release, and release from a conventional tablet or 
capsule. 
  Figure 6 shows comparative blood level profiles obtained from administration 
of conventional, controlled and sustained release dosage forms.  The conventional tablet or 
capsule provides a single and transient burst of drug. A pharmacological effect is seen as 
long as the amount of drug is within the therapeutic range. Problems occur when peak 
concentration is above or below this range, especially for drugs with narrow therapeutic 
windows. 
   The slow first order release obtained by sustained release preparation is 
generally achieved by slowing the release of drug from a dosage form. In some cases this 
is accomplished by a continuous release process; however system that release small bursts 
of drug over a prolonged period can mimic the continuous system.  
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SUSTAINED RELEASE (SR) DRUG DELIVERY SYSTEMS 4 
  Sustained release drug delivery systems can be defined as any dosage form 
that prolongs the therapeutic activity of the drug by continuously releasing medication 
over an extended period of time. In absence of suitable clinical evidence of this therapeutic 
effect it can be defined as any dosage form that gives prolongation of the drug levels in the 
blood. The major advantage of this category is that, in addition to the convenience of 
reduced frequency administration, it provides levels that are devoid of the peak and valley 
effect. 
   By providing smooth plasma level of drug over longer period of time, sustained 
release drug delivery technology can minimize side effects, improve efficacy and by 
enabling once daily dosing – maximize patient compliance. 
 
ADVANTAGES  
   Sustained release products offer many potential benefits over conventional 
dosage formulations e.g, 
 
1. Sustained blood levels 
• For drugs with relatively short half lives, the use of sustained release products 
may maintain therapeutic concentrations over prolonged periods. 
2. Dosage frequency reduction  
• Minimize or eliminate local side effects. 
• Minimize or eliminate systemic side effects. 
• Obtain less potentation or reduction in drug activity with chronic use. 
• Minimize drug accumulation with chronic dosing. 
3. Improve patient compliance 
• A reduction in the number of daily doses offered by sustained release products  
 has the potential to improve compliance. 
4. Improve efficiency in treatment 
• Improve control of condition i.e., reduced fluctuation in drug levels 
• Improve bioavailability of some drugs. 
• Make use of special effects.  Eg., sustained release of aspirin for morning relief 
of arthritis by dosing before bedtime.  
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5. Economy i.e. reduction in health care costs 
• The average cost of treatment over an extended time period may be less, with 
less frequency of dosing, enhanced therapeutic benefits and reduced side 
effects. 
• The time required for health care professional to dispense and administer the 
drug and monitor patient is also reduced. 
 
DISADVANTAGES 
1. Sustained release products contain a higher drug load and thus any loss of integrity of   
the release characteristics of the dosage form has potential problems. 
2. The larger size of sustained release products may cause difficulties in ingestion or 
transit through the gut. 
3. Sustained release products may cause decreased systemic bioavailability in comparison 
to conventional dosage forms, which may be due to incomplete release, increased first 
pass metabolism, increased instability, insufficient residence time for complete release, 
site specific absorption, pH dependent stability etc.  
4. Possibility of dose dumping due to food, physiologic or formulation variables or 
chewing or grinding of oral formulations by the patient and thus increased risk of 
toxicity. 
 
RELEASE MECHANISM FOR SUSTAINED AND CONTROLLED RELEASE 
PRODUCTS 10, 11  
                       Based on the release mechanism these are classified as follows 
 Diffusion controlled products 
 Dissolution controlled products 
 Erosion products 
 Osmotic pump systems 
 Ion exchange resins 
 
01. Diffusion controlled products 
                In these systems, there is a water soluble polymer, which controls the flow of 
water and the subsequent release of dissolved drug from the dosage form. Diffusion occurs 
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when a drug passes through the polymer that forms the controlled release device. The 
diffusion can occur through the pores in the polymer matrix or by passing between 
polymer chains. These are broadly classified into two categories. 
A. Reservoir devices 
B. Matrix devices 
The basic mechanisms of drug release from these two systems are fundamentally different. 
A. Reservoir Devices 
               In this system a water insoluble polymeric material encases a core of drug. Drug 
will partition into the membranes and exchange with the fluid surrounding the particles or 
tablet. 
             The active ingredient is released to the surrounding environment by diffusion 
process through the rate limiting membrane. In the reservoir systems the drug delivery rate 
remains fairly constant. 
.  
Fig. 7: Drug delivery from typical reservoir devices: (a) Implantable or oral 
systems and (b) Transdermal systems 
 
B. Matrix Devices 
                      In the matrix device the drug or active ingredient is dispersed in polymer 
matrix to form a homogenous system known as matrix system.  Diffusion occurs when the 
drug passes from the polymeric matrix into the external environment. As the release 
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continuous, its rate normally decreases with the system, since the active ingredient has 
progressively longer distance to travel and therefore requires a long diffusion time to 
release. 
 
Fig. 8: Drug delivery from a typical matrix drug delivery system 
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2. LITERATURE REVIEW 
 
REVIEW FOR BILAYER TABLETS 
1) Ramana G et al. 12 formulated and evaluated the sustained release bilayer tablets of 
Ambroxol hydrochloride. The tablets were prepared by direct compression technique 
using sodium starch glycolate as super disintegrant for fast release layer and CR grade 
polymers such as HPMC K4M , Ethyl  cellulose independently and also in combinations. 
The formulation containing Drug: HPMC: EC at the ratio of 1:0.5:30% exhibited an initial 
burst effect followed by sustained release over a period of 12 hours. The dissolution data 
of various formulations were fitted into Higuchi and Peppas models, which are linear with 
Higuchi’s plot and “n” values obtained from Peppas were within 0.45 to 0.89 indicate the 
mechanism of drug release diffusion coupled with erosion.   
2) Brijesh Patel et al. 13 designed and evaluated Mucoadhesive controlled release oral 
bilayer tablets of Indomethacin. Solid dispersion of Indomethacin was prepared using PEG 
6000 to improve the solubility of Indomethacin. Bilayer tablets were prepared using direct 
compression technique employing Ac-Di-Sol as superdisintegrant for immediate release 
layer and Carbapol 934 LR, HPC for sustained release layer. The polymers were used 
alone or in combinations. By varying the concentrations of polymers several batches were 
formulated. The batch containing the mixture of Carbapol 934 LR and HPC in the ratio of 
1:1 showed a better drug release than individual formulation containing Carbapol 934 LR 
and HPC. The drug release kinetics was studied and it was found that the drug was 
released from the formulation by diffusion. 
3) Deelip Derle et al. 14 formulated and evaluated buccoadhesive bilayer tablets of 
Propranolol hydrochloride. The tablets were prepared by direct compression method. 
Bioadhesive polymers such as sodium alginate and Carbapol 971P were used and ethyl 
cellulose was used as an impermeable backing layer. The tablets were prepared in two 
steps, initially the drug polymer mixture was compressed after that the backing layer of 
ethyl cellulose was placed over the compact and then compressed into bilayer tablets. 
Tablets containing sodium alginate and Carbapol 971P in the ratio of 5:1 showed the 
maximum percentage of in vitro release without disintegration for 12 hours. The 
mechanism of drug release was found to follow zero-order kinetics.  
Literature Review 
 
Department of Pharmaceutics, Madras Medical College Page 18 
 
4)  Nagaraju R et al. 15 formulated and evaluated bilayer sustained release tablets of 
Salbutamol and Theophylline. Wet granulation technique was employed for preparation of 
granules. PVP K30 in Isopropyl alcohol was used as a binder. Various polymers such as 
HPMC K4M, HPMC K100M, Xanthan gum, Ethyl cellulose and HPMC-P were studied. 
HPMC-P and HPMC K4M were found to be best in controlling the release. 
5) Ashish A Pahade et al. 16 designed and developed bilayer sustained release tablets of 
Isosorbide mononitrate. Wet granulation technique was employed for preparing granules 
using PVP K30 as binder. The immediate release granules were prepared using 
Croscaramellose Sodium as superdisintegrant. Hydrophilic and hydrophobic matrix 
material such as HPMC K4M and Polyox WSR 303 was used for preparing sustained 
release layer. The influence of hydrophilic and hydrophobic polymer and granulation 
technique was studied. By varying the concentrations of HPMC K4M four formulations of 
bilayer tablets were prepared. The formulation containing HPMC K4M at a concentration 
of 19.33% w/w was selected as the optimized batch as it showed better in vitro release 
profile compared to other batches. Similarly by varying the concentration of hydrophobic 
polymer Polyox WSR 303 three batches of bilayer tablets were prepared. The formulation 
containing 15% w/w showed better in vitro release profile and thus it was optimized for 
further studies. 
6) Bhavesh Shiyani et al. 17 formulated and evaluated bilayer tablets of Metoclopramide 
hydrochloride (MTH) and Ibuprofen (IB).  MTH was formulated as immediate release 
layer by using various disintegrants like Ac-Di-Sol, Polyplasdone XL, Explotab, Agar and 
Gellan Gum. The formulation containing Ac-Di-Sol was optimized for preparing Bilayer 
tablets. Sustained release layer of IB was formulated using hydrophilic matrix HPMC 
K4M, buffering agent sodium bicarbonate and PVP K30. By increasing the concentrations 
of HPMC K4M and PVP K30 the release was reduced. By inclusion of buffering agent 
sodium bicarbonate the release was increased as well as there is reduction in gastric 
irritation as IB is a weak acid. The drug release mechanism was found to be Quasi-Fickian 
diffusion. 
7) Narendra C et al. 18 studied the optimization of bilayer floating tablets of Metoprolol 
Succinate. A 23 factorial design was used for optimizing the formulation with respect to 
polymer-drug (X1), polymer-polymer (X2) and different viscosity grades of s polymer 
ratio(x3) as independent variables. Four dependent variables are percentage of drug 
release at 8 hours, t50%, diffusion coefficient and floating time. X1 and X2 significantly 
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affected the floating time and release properties, but the effect of different viscosity grades 
of HPMC K4M and HPMC K100M was not significant. 
8) Vinoth kumar G et al. 19 formulated and evaluated bilayer tablets of Cefixime 
trihydrate and Dicloxacillin sodium. Wet granulation technique was used to formulate 
granules for both the layers. Cefixime trihydrate was formulated as immediate release 
layer using Croscaramellose sodium as superdisintegrant. Sustained release layer of 
Dicloxacillin sodium was formulated by varying the concentrations of HPMC K4M and 
HPMC K100M. Nine batches of bilayer tablets were prepared. All the formulations were 
compared with the innovator product in respect to all tablet properties such as hardness, 
friability, disintegration time and dissolution. The percentage drug release of formulation 
F5 showed drug release comparable to the innovator product disintegration time and drug 
release and thus it was optimized and kept for further studies. 
9) Gohel MC et al. 20 fabricated and evaluated bilayer tablets containing conventional 
Paracetamol and modified release Diclofenac sodium. A 23 full factorial design was 
adopted using the amount of polyethylene glycol, microcrystalline cellulose and 
Crospovidone as independent variables for fabricating Paracetamol tablets. Diclofenac 
sodium tablets were prepared using varying concentrations of HPMC K4M as matrixing 
agent. The results of analysis of variance showed that the friability of Paracetamol was 
distinctly influenced by the formulation variables. Diclofenac sodium layer was optimized 
by comparing the formulation with the innovator product. The optimized layers were 
finally compressed into bilayer tablets. The tablets were subjected for drug release 
mechanism. It was found out that the bilayer tablets followed Korsmeyer-Peppas model. 
10)  Naeem MA et al. 21 developed and evaluated controlled release bilayer tablets 
containing microencapsulated Tramadol and Acetaminophen. Microencapsulation based 
phase separation technique using medium viscosity ethyl cellulose was employed to 
formulate separate Microparticles for extending the release of both drugs. The 
Microparticles of both the drugs were prepared separately and were used for formulating 
the bilayer tablets. The optimized batches were subjected for studying the release 
mechanism. The release kinetics was followed by Higuchi model with a good R2 value. 
The tablets were subjected to accelerated stability studies for 3 months. 
11)  Nirmal J et al. 22 studied the formulation and evaluation of bilayer tablets of 
Atorvastatin calcium and Nicotinic acid. Atorvastatin calcium was formulated as 
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immediate release layer using Croscaramellose sodium as superdisintegrant. Nicotinic acid 
was formulated as sustained release layer using HPMC K100M in varying concentration.  
12) Remya PN et al. 23 studied the formulation and evaluation of bilayer tablets of 
Ibuprofen and Methocarbamol. Wet granulation technique was employed for preparing 
granules using PVP K 30 as binder. The bilayer tablets were film coated using Advantia 
prime clear film coat material. Nine batches of bilayer tablets were prepared. The in vitro 
release of the bilayer tablets were compared with the innovator and the release kinetics of 
formulation 8 were taken as optimized formulation due to its higher dissolution rate and 
complied all other parameters with the official specifications. 
13) Jadhav RT et al. 24 formulated and evaluated bilayer tablets of Piracetam and 
Vinpocetine. Wet granulation technique was employed for formulation of both layers. 
PVP K 30 was used as binder for preparing Piracetam granules and maize starch was used 
as binder for preparing Vinpocetine granules. Sodium starch glycolate was used as 
superdisintegrant. Bilayer tablets were optimized based on the disintegration time and 
comparison of the dissolution profile with the innovator product. 
14)  Hiremath JG et al. 25 studied the preparation and physicochemical characterization 
of Simvastatin loaded Mucoadhesive bilayer tablets. Tablets were prepared by direct 
compression technique by using mucoadhesive polymers such as Carbapol 934, HPMC 
and PVP in varying concentrations. Ethyl cellulose was used as backing membrane layer 
because of its water impermeable nature. The core layer was composed of drug and 
polymer in varying concentrations. To the backing layer Carbapol 934 and PVP K 32 was 
added to avoid premature cracking. FTIR and DSC were done to study the compatibility of 
the drug and excipients. F3 and F9 formulations were selected as optimized batch. F3 was 
selected for in vitro permeation studies based on its maximum drug release F9 formulation 
was selected based on the in vitro drug release, swelling index and good bioadhesive 
strength. The optimized batches were subjected to drug release kinetics. 
15) Ajit S Kulkarni et al. 26 prepared the floating bilayer tablets of Diltiazem 
hydrochloride and Lovastatin. Direct compression technique was employed for preparing 
bilayer tablets. Lovastatin was formulated as immediate release layer using sodium starch 
glycolate as super disintegrant and Diltiazem hydrochloride was formulated as sustained 
release layer comprising of HPMC K4M and Xanthan gum as the release retarding 
polymers. Sodium bicarbonate was used as a gas generating agent. All the formulations 
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released the Lovastatin within 30 minutes. HPMC K4M and Xanthan gum sustained the 
release for 12 hours. 
16) Ziyaur Rahaman et al. 27 developed the bilayer floating tablets of Captopril using 
direct compression technique. The floating layer was formulated with various HPMC 
grades (K4M, K15M and K100M) and effervescent mixture of citric acid and sodium 
bicarbonate. The sustained release layer comprised of Captopril and various polymers 
such as HPMC K15M, PVP K30 and Carbapol 934P alone or in varying combination with 
the drug. Final formulation released approximately 95% of drug in 24 hours, while the 
floating time was 10 min and the tablet remained floatable throughout the studies. Placebo 
formulation containing barium sulphate in the release layer administered to human 
volunteers for in vivo X-ray studies showed the BFT had significantly increased the gastric 
residence time. 
17) Ankarao A et al. 28 prepared the Buccoadhesive bilayer tablets of Metoprolol tartrate. 
Core tablet of Metoprolol tartrate was prepared by direct compression technique using 
HPMC K4M, SCMC and Carbapol 934 as bioadhesive polymers to impart mucoadhesion 
and ethyl cellulose to act as an impermeable backing layer. Six formulations containing 
the bioadhesive polymers were prepared. The formulation F2 and F5 were optimized and 
obeyed zero order release kinetics with Non-Fickian diffusion. 
18) Ankarao A et al. 29 studied the formulation and evaluation of Buccoadhesive Bilayer 
tablets of Carvedilol. Direct compression was employed for preparing core tablets using 
HPMC K4M, SCMC, and Carbapol 934 as bio-adhesive polymer to impart mucoadhesion. 
Ethyl cellulose was used as impermeable backing membrane. The formulations containing 
HPMC and SCMC were optimized based on the buccoadhesive property and release 
characteristics.     
 
REVIEW FOR METFORMIN HYDROCHLORIDE 
 
19) Bagyalakshmi J et al. 30 developed a bilayer formulation containing Metformin 
hydrochloride and Glipizide. Metformin hydrochloride was formulated as sustained 
release layer using varying grades of HPMC (K4M, K15M, and K100M). Glipizide was 
formulated as immediate release layer. Due to the poor solubility of Glipizide, Solid 
dispersion technique using sodium starch glycolate was employed using Kneading method 
to improve the solubility of glipizide. The solid dispersion system was characterised by 
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FT-IR and in vitro dissolution studies. Both the layers were optimized separately the 
optimized batches were then finally compressed into bilayer tablets. 
20) Kotta Kranthi Kumar et al. 31 designed, developed and characterized sustained 
release of Metformin and Gliclazide bilayer tablets. Wet granulation technique was 
employed using various grades of HPMC for preparing granules. Trail batch of Metformin 
hydrochloride containing HPMC K100M and trail batch of Gliclazide containing HPMC 
K15M was optimized for preparing bilayer tablets. The tablets were compared with the 
innovator product. 
21)  Rajendran NN et al. 32 formulated and evaluated sustained release bilayer tablets of 
Metformin hydrochloride and Pioglitazone hydrochloride. Pioglitazone HCl was 
formulated as immediate release layer by direct compression method using sodium starch 
glycolate and Croscaramellose sodium. Sustained release layer of Metformin 
hydrochloride was formulated by wet granulation technique using different viscosity 
grades of HPMC (K4M & K100M). The immediate release layer containing varying super 
disintegrants was compressed separately and they were compared with the innovator 
product. The formulation containing sodium starch glycolate (5%) was optimized as it 
matched with the burst release of the innovator product. The sustained release layer was 
formulated by varying the concentration of HPMC K4M and HPMC K100M. The 
formulated tablet was compared with the innovator. The concentration of HPMC K100M 
(8.82%) and HPMC K4M (4.70%) was optimized as it showed the comparable release 
profile with the innovator. The optimized formulations were finally compressed into 
bilayer tablets and were studied for drug release kinetics. 
22) Ramesh et al. 33 formulated and evaluated bilayer sustained release tablets of 
Metformin hydrochloride and Pioglitazone. Dry granulation technique was employed for 
formulation of immediate release layer using Croscaramellose sodium in varying 
proportions. Sustained release layer granules were formulated by wet granulation 
technique using bio-adhesive polymers such as Sodium carboxy methyl cellulose and 
various grades of HPMC (K4M & K15M). The tablets were optimized separately and the 
optimized batches were finally compressed into bilayer tablets. The bilayer tablets gave a 
bimodal release indicating the immediate release followed by sustained release. The 
optimized batch was subjected to release kinetics to study the release mechanism. 
23)  Durga Prasad Pattanayak et al. 34 designed bilayer formulation of Metformin 
hydrochloride and Glimepiride. Glimepiride was formulated as immediate release layer 
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and was optimized separately. Metformin was formulated as sustained release layer. Two 
different matrix formulations were developed, one matrix layer with hydrophilic swellable 
layer such as HPMC and another matrix layer with hydrophobic layer such as PEO. The 
sustained release profile of HPMC matrix system was better than PEO matrix system. 
Thus it was optimized and compared with the innovator product. The optimized 
formulations were finally compressed into bilayer tablets. The tablets were subjected to 
study the drug release mechanisms. The formulation exhibited zero order kinetics and 
followed Non-Fickian transport. 
24)  Yamsani Madhusudan Rao et al. 35 studied the formulation and release 
characteristic of a bilayer matrix tablet containing Glimepride immediate release 
component and Metformin hydrochloride as sustained release component. Immediate 
release layer was formulated by direct compression using sodium starch glycolate as super 
disintegrant. Sustained release layer was formulated in 5 batches by wet granulation 
technique using HPMC K4M, SCMC as matrix forming polymer and PVP K 30 as binder. 
Batch 5 containing a mixture of Hydrophilic polymers in the ratio of 7.05:26.4% released 
the drug in the controlled manner and thus optimized and evaluated for further studies. 
25) Madhabhai Manordas Patel et al. 36 designed and developed bilayer gastro retentive 
tablets containing Metformin hydrochloride and Glipizide for the treatment of Type II 
diabetes. Direct compression was employed for formulating both the layers. Metformin 
hydrochloride was formulated as sustained release layer using various grades of HPMC. 
Glipizide was formulated as immediate release layer using various superdisintegrants i.e. 
Croscaramellose Sodium, Crospovidone and sodium starch glycolate. Sodium starch 
glycolate (5%) was optimized as superdisintegrant for immediate release layer based on 
faster disintegration time.  32 full factorial designs were used to optimize sustained release 
formulations of Metformin hydrochloride. The ratio of polymer blend (X1) and content of 
gas generating agents (X2) was chosen as independent variables. Among the different 
grades of HPMC investigated, the viscosity of the polymer affects the drug release. From 
the results we can conclude that prepared bilayer tablets showed desirable release profile, 
good floating and sustained effect in stomach. 
26)  Saptarshi Dutta et al. 37 studied the formulation and evaluation of Metformin 
hydrochloride sustained release matrix tablets. Dry granulation technique was employed 
using various grades of HPMC (K4M & K100M). The formulation containing HPMC 
K100M alone showed release profile comparable to the marketed product for a period of 
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12 hours and thus it was optimized. The optimized formulations were studied for drug 
release kinetics which showed that the formulation released the drug by diffusion. The 
tablets were kept for accelerated stability studies.  
27) Senthilkumar KL et al. 38 formulated, developed and evaluated Metformin 
hydrochloride sustained release tablets. Wet granulation technique was employed for 
formulation of tablets by using various grades of HPMC (K4M & K100M) as release 
retarding polymers and PVP K 30 as binder. The formulation containing        13% HPMC 
K100 was optimized as it fulfilled the requirements for a sustained release tablets. 
28) Jayaprakash S et al. 39 studied the formulation and evaluation of bilayer tablets of 
Metformin hydrochloride. Direct compression technique was employed for formulation of 
bilayer tablets using sodium starch glycolate and Crospovidone as super disintegrant for 
immediate release layer and HPMC K4M as release retardant polymer for sustained 
release layer. Formulation containing HPMC K4M, SCMC as binder for sustained release 
layer was optimized. Immediate release layer containing Crospovidone and sodium starch 
glycolate in combination was optimized. The optimized formulation was finally 
compressed into bilayer tablets and its drug release mechanism was studied and was found 
out that it followed swelling mediated diffusion. The formulations were kept for 
accelerated stability studies for a period of 3 months.  
29) Manju Nagpal et al. 40 formulated and evaluated of Metformin Oro-dispersible 
tablets. Direct compression method using super disintegrant approach, effervescent 
approach and sublimation approach was used for formulation of tablets. Formulation 
prepared by effervescent approach showed improved disintegration time and dissolution 
profile and thus it was taken as an optimized batch. 
30) Prameela Rani A et al. 41 studied the formulation and evaluation of Orodispersible 
Metformin tablets. A comparative study on Isphagula husk and Crospovidone as 
superdisintegrants. Direct compression technique using superdisintegrants was used for 
the formulation. The batch prepared using Isphagula husk (8%) was taken as an optimized 
formulation as it showed rapid disintegration time, hardness and good dissolution profile. 
31) Sunil Kumar et al.42 formulated and evaluated of extended release Metformin 
tablets. Wet granulation technique was employed for the formulation of extended release 
tablets using HPMC K100M as polymer and stearic acid and IPA as binder agent. Seven 
batches of formulations were prepared. Batch 7 was taken as an optimized batch as it 
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showed better release profile compared to other batches. The optimized batch was kept for 
accelerated studies for a period of 3 months. 
32)  Kamlesh J Wadher et al.43 formulated and evaluated of sustained release matrix 
tablets of Metformin hydrochloride using pH dependent and pH independent methacrylate 
polymers. Direct compression technique was employed for formulation of tablets using pH 
dependent (Eudragit L-100 and S-100) and pH independent (Eudragit RLPO and RSPO) 
polymer combinations. Various formulations were prepared using the polymers alone or in 
combination. Formulation containing Eudragit S-100 and Eudragit RLPO in the ratio of 
0.3:0.7 w/w gave a sustained release pattern. 
33) Margret Chandira et al.44 studied the formulation and evaluation of extended release 
tablets containing Metformin hydrochloride. Wet granulation technique was employed for 
the formulation of tablets using HPMC K100M and Carbapol 71 G in combinations. Ten 
batches of formulations were prepared using the above polymers. Batch 10 showed the 
release profile comparable with the innovator product. The optimized formulation was 
kept for accelerated stability studies. 
34) Ashok Kumar A et al. 45 formulated and evaluated Mucoadhesive microcapsules of 
Metformin hydrochloride with Gum Karaya. The microcapsules were prepared with a coat 
of alginate and Gum Karaya by employing Ionotropic Gelation process and Emulsification 
Ionotropic Gelation process. The microcapsules prepared by Emulsification Ionotropic 
Gelation process was found to be spherical which showed slow and extended release over 
a period of time. Drug release was diffusion controlled and followed zero- order kinetics. 
35)  Lian-Dong Hu et al. 46 prepared and evaluated sustained release Metformin 
hydrochloride pellets. Centrifugal granulation was used to prepare pellets. The influence 
of surface modification by talc, the effects of Eudragit types and ratios, as well as the 
correlation between in vitro release and in vivo absorption were investigated in detail. The 
blend was coated with Eudragit L30D-55 and Eudragit NE30D at 7% or 10% level. The 
coated pellets showed good release profile. The absorption site specificity of Metformin 
hydrochloride in the intestine, three dissolution media, 0.1 N HCl, distilled water and 
phosphate buffer (pH 6.8) was used and the release was studied. 
 
 
 
 
Literature Review 
 
Department of Pharmaceutics, Madras Medical College Page 26 
 
 REVIEW FOR LOSARTAN POTASSIUM  
36) Doddayya Hiremath et al. 47 designed and characterized of bilayer controlled release 
matrix tablets of Losartan potassium. Direct compression technique was employed for 
formulating bilayer tablet. Losartan potassium was formulated as immediate release as 
well as sustained release layer. Immediate release layer was formulated using Sodium 
starch glycolate as super disintegrant. Sustained release layer was formulated using 
polymers such as Xanthan gum and Gum Karaya in varying proportions. Immediate 
release layer containing Sodium starch glycolate (6%) was optimized. Sustained release 
layer containing polymer in equal proportions was optimized for final preparation of 
bilayer tablets. The optimized formulations were subjected to study the drug release 
mechanisms. The tablets showed zero order release Kinetics and Non-Fickian diffusion. 
37) Varma MM et al. 48 studied the formulation and evaluation of Losartan potassium 
matrix tablets for controlled release. Tablets were prepared by direct compression 
technique using Carbapol 934P and HPMC K100M as polymers. 11 formulations were 
prepared totally and all the batches showed the release profile for a period of 24 hours.  
38) Ramya Chakrahari et al. 49 formulated and evaluated of sustained release matrix 
tablets of Losartan potassium. Wet granulation technique was employed using different 
polymers such as HPMC, Ethyl cellulose and Xanthan gum. Nine formulations were 
prepared. The formulation containing HPMC was optimized as it released the drugs for a 
period of 10 hours. The drug followed zero order release and non-Fickian transport. The 
optimized tablets were kept for accelerated stability studies. 
39) Prajapati BG et al. 50 studied the formulation and in vitro evaluation of once daily 
sustained release matrix tablets of Losartan potassium. Direct compression technique was 
employed using polymers HPMC K4M, HPMC K200M, Eudragit RSPO. 8 batches were 
prepared by varying the polymer concentrations. Batch 4 containing HPMC K4M, HPMC 
K200M, Eudragit RSPO was optimized based on the release profile as it sustained the 
release for a period of 24 hours. 
40) Mohanthy BR et al. 51 developed and optimized Losartan potassium tablets. Direct 
compression technique was employed using sodium starch glycolate as super disintegrant. 
Totally 8 formulations were prepared. Formulation 8 was selected as optimized batch as 
the release profile was comparable with the innovator product. The optimized tablets were 
kept for accelerated stability studies.  
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41) Rajesh Gollapudi et al. 52 formulated and evaluated sustained release matrix tablets 
of Losartan potassium. Direct compression method was followed for preparing tablets 
using Eudragit RLPO, RSPO and Ethyl cellulose individually or in combination. The 
formulations containing Eudragit RLPO and RSPO were optimized based on the in vitro 
release profile and f2 factor. Mathematical analysis of the release kinetics indicated that 
drug release mechanism was Fickian diffusion. 
42) Suhas M Kakade et al. 53 studied the formulation and evaluation of mouth dissolving 
tablets of Losartan potassium. Direct compression technique was employed for preparing 
tablets using super disintegrants like Polyplasdone XL 10, Croscaramellose sodium and 
Explotab in different concentrations. The tablets were optimized based on the 
disintegration time. Polyplasdone XL 10 has faster disintegration time compared to the 
other two superdisintegrants. 
43) Mohd Azharuddin et al. 54 formulated and evaluated controlled release matrix 
tablets of antihypertensive drug using natural and synthetic hydrophilic polymers. Direct 
compression technique was employed for preparing tablets using HPMC K4M and 
Xanthan gum. The polymers were used alone or in combinations for the formulation of 
tablets. Nine batches were prepared and the 9th batch containing the polymers in equal 
proportions was optimized as it sustained the release for a period of 24 hours. 
44) Lingaraj S Danki et al. 55 developed and evaluated gastro retentive drug delivery 
system of Losartan Potassium. Wet granulation technique was used for formulating the 
tablets by employing polymers like HPMC K4M, HPMC K 15M, Carbapol 934P and 
sodium alginate at different drug to polymer ratios with and without gas generating like 
sodium bicarbonate and citric acid. Various formulations were prepared using the 
polymers and gas generating agents. The formulation containing HPMC K4M as polymer 
and gas generating agent in the ratio of 1:1 showed shorter floating lag time, good 
swelling property and good release profile. The optimized formulation was subjected to 
further short time stability studies. 
45) Vijaya Muthumanikandar R et al. 56 developed and evaluated Buccoadhesive 
tablets of Losartan Potassium. Wet granulation technique was employed for formulation of 
tablets using Carbapol 934P, HPC, sodium alginate and SCMC as bioadhesive polymer. 
The formulation containing Carbapol and HPC in the ratio of 30%:20% was optimized 
based on its adequate bioadhesiveness, swelling properties and release profile. The 
optimized formulation was studied for drug release kinetics. The formulation followed 
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first order release kinetics. The optimized formulation was sealed in aluminium packing 
and kept for accelerated stability studies for a period of 3 months. 
46) Suman A et al. 57 studied the formulation and in vitro evaluation of Losartan 
potassium floating tablets. Effervescent technique was used for formulating granules using 
varying grades of HPMC(K4M, K15M & K100) and using gas generating agent.12 
formulations were prepared using the varying grades of HPMC. The formulation 
containing HPMC K100 (12%w/w of drug) and sodium bicarbonate (9%) showed rapid 
floating time, higher swelling and better release profile compared to the other formulations 
containing HPMC K4M and HPMC K15M. The optimized formulation was subjected to 
release kinetics.  
47) Reeta Rani Thakur et al. 58 studied the formulation evaluation and optimization of 
mouth dissolving tablets of Losartan potassium. Direct compression technique was 
employed for the formulation of tablets using sodium starch glycolate as Super 
disintegrant and sodium bicarbonate and citric acid as effervescent agents. Nearly ten 
formulations (A-J) were formulated and evaluated for precompression and post 
compression parameters and it was concluded that formulation C satisfied the criteria in all 
aspects and thus it was optimized. 
48) Pavithra TK et al. 59 formulated and evaluated hydrogel based oral controlled drug 
delivery system of antihypertensive drug. Tablets were prepared by wet granulation 
technique. Simplex lattice design was used to develop the matrix tablets and evaluate the 
relationship and influence of different content levels of HPMC, Eudragit RSPO, Eudragit 
RLPO and ethyl cellulose in order to achieve zero order release of drug. The combination 
of HPMC with Eudragit sustained the release for a period of 8 hours. The tablets were then 
studied for drug release kinetics. 
49) Permender Rathee et al. 60 studied the stability indicating UV- Spectrophotometric 
methods for simultaneous determination of Losartan potassium and Hydrochlorothiazide 
in pharmaceuticals. Two new stability indicating methods have been described for 
simultaneous assay of Losartan potassium and Hydrochlorothiazide in bulk and tablet 
formulation using 0.1N HCl as solvent. Method A is based on simultaneous equation and 
Method B is based on Q absorbance ratio method. Both the methods have been developed 
and validated. Both the methods provide good sensitivity comparable to that achieved in 
sophisticated techniques such as HPLC. Thus these methods can be used routinely for 
determination of bulk sample and tablets. 
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50) Rudy Bonfilio et al. 61 studied Losartan potassium dissolution testing for drug release 
evaluation pharmaceutical capsules using HPLC and UV Spectrophotometry. A 24 
factorial design was carried out to optimize dissolution condition and phosphate buffer pH 
6.8 as dissolution medium and stirring speed of 50rpm. Spectra of Losartan potassium was 
built in the range of 400 to 200nm using 1cm quartz cuvettes. The maximum peak was 
obtained at 205nm. 
  
 
 
 
 
 
 
 
 
      Aim & Plan of Work 
 
Aim and Plan of work  
 
Department of Pharmaceutics, Madras Medical College Page 30 
 
3. AIM AND PLAN OF WORK 
 
AIM OF THE PROJECT WORK 
01. The main objective of the present study is to develop bilayer tablets containing 
Losartan potassium for immediate release and Metformin hydrochloride for sustained 
release for diabetic patients having hypertension. 
02. To provide effective, safe and stable pharmaceutical oral formulation containing an 
Antihypertensive drug Losartan potassium as immediate release layer and oral 
hypoglycemic drug Metformin hydrochloride as sustained release layer for effective 
treatment of hypertension in patients having Type-II diabetes mellitus. 
 
PLAN OF WORK    
 Preformulation studies. 
• Physical and Chemical compatibility studies. 
 Calibration curve. 
 Pre compression studies of the drug and blends of Losartan potassium. 
 Formulation of Immediate release (IR) tablets. 
 Post compression studies of IR tablets for physical parameters like uniformity of  
 weight, thickness, diameter, hardness and friability. 
 Determination of drug content of IR tablets. 
 Disintegration studies of IR tablets. 
 In vitro dissolution study of IR tablets. 
 Pre compression studies of the drug and blends of Metformin hydrochloride. 
 Formulation of sustained release (SR) tablets. 
 Post compression studies of SR tablets for physical parameters like uniformity of 
 weight, thickness, diameter, hardness and friability. 
 Determination of drug content of SR tablets. 
 In vitro dissolution study of SR tablets. 
 Formulation of bilayer tablets from the optimized batches of IR and SR layer. 
 Post compression studies of bilayer tablets for physical parameters like uniformity of 
 weight, thickness, diameter, hardness and friability. 
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 Determination of drug content by simultaneous equation method. 
  In vitro dissolution study of bilayer tablets. 
  Evaluation of release kinetics of optimized bilayer formulation. 
 Determination of stability of bilayer tablets as per ICH guidelines.  
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4. RATIONALE 
RATIONALE FOR SELECTION OF AT1 BLOCKER (LOSARTAN) OVER      
ACE INHIBITORS  
                Losartan potassium is a competitive antagonist to Angiotensinogen II and 
devoid of partial agonistic activity and 10,000 times more selective for AT1 than AT2 
receptors.62 Pharmacologically AT1 antagonist differs from ACE inhibitors in the 
following ways. AT1 antagonists do not interfere with the degradation of bradykinin and 
other ACE substrates thus there is no rise in level or potentation of bradykinin. AT1 
antagonist results in more complete inhibition of AT1 receptor activation than ACE 
inhibitors. ACE inhibitor associated cough is not seen in AT1 antagonist and angioedema 
is rare.63 All of these make AT1 antagonists better over ACE inhibitors. 
RATIONALE FOR SELECTION OF METFORMIN HYDROCHLORIDE FOR 
TYPE II DIABETES 64  
Metformin is Antihypergylcemic, not a hypoglycemic. It does not cause insulin 
release from pancreas and generally does not cause hypoglycemia even in large doses. 
Metformin reduces glucose levels primarily by decreasing hepatic glucose production and 
by increasing insulin action in muscle and fat. Metformin given alone improves glycemic 
control and lipid concentrations in patients who respond poorly to diet or to sulfonylurea 
alone. Metformin has minimal side effects and a safer drug to treat diabetes. 
 
RATIONALE FOR SELECTION OF LOSARTAN POTASSIUM AND METFORMIN 
HYDROCHLORIDE FOR FORMULATING BILAYER TABLETS  
 Most patients with type II diabetes have a prior history of cardiovascular 
complications and hypertension accounts for 75% in patients with type II diabetes.66 
Patients with other complications have to take more number of drugs. In order to reduce 
the polytherapy to monotherapy in patients with hypertension and type II diabetes and to 
improve patient compliance bilayer tablets were selected where two drugs can be given in 
combination. One such attempt was the formulation of bilayer tablets of Losartan 
potassium and Metformin hydrochloride.  
  
 
 
 
 
 
 
 
 
      Profiles 
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5. PROFILES 
DISEASE PROFILE  
 DIABETES MELLITUS 
Definition 
  Diabetes mellitus is not a single disease entity but rather a group of metabolic 
disorders sharing a common underlying feature of hyperglycemia. Hyperglycemia in 
diabetes results from defects in insulin secretion, insulin action, or most commonly both. 
DM consists of a group of disorders characterized by hyperglycemia; altered metabolism 
of lipids, carbohydrates, and proteins; and an increased risk of complications from 
vascular disease.64 The chronic hyperglycemia and attendant metabolic dysregulation may 
be associated with secondary damage in multiple organ systems, especially the kidneys, 
eyes, nerves and blood vessels. 
 
Fig. 9: Complications of Type II diabetes 
 
Epidemiology 64 
   The incidence of diabetes varies widely throughout the world. In the 
U.S., 5–10% of all diabetic patients have type 1 DM, with an incidence of 18/100,000 
inhabitants/year. The vast majority of diabetic patients (~90% in the U.S.) have type 2 
DM. Incidence rates of type 2 DM increase with age, with a mean rate of about 
440/100,000/year by the sixth decade in males in the U.S. According to American 
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Diabetes Association, Diabetes affects over 20 million children and adults, or 7% of the 
total population in the United States are unaware that they have hyperglycemia. 
Approximately 1.5 million new cases are diagnosed each year in the United States, and 
diabetes is the leading cause of end stage renal disease, adult onset blindness and non 
traumatic lower extremity amputations. 6 million people in the USA have Type 2 diabetes; 
India has a whopping 30 million and more people who are diabetics. According to a WHO 
estimate released in 1998, India will have the maximum number of diabetics in the world 
by 2025. 
 
Classification 65  
1) Type 1 Diabetes Mellitus or Insulin Dependent Diabetes Mellitus 
2) Type 2 Diabetes  Mellitus or Non-Insulin Dependent Diabetes Mellitus 
3) Type 3 Diabetes Mellitus (due to drugs such as Glucocorticoids, Thiazide diuretics, 
Protease inhibitors used to treat HIV, Diazoxide, Growth hormone etc.) 
4) Type 4 Diabetes mellitus or Gestational Diabetes Mellitus. 
 
Pathogenesis of Type 2 Diabetes Mellitus 
   Type 2 diabetes is a prototypic multi factorial complex disease. 
Environmental factors, such as a sedentary life style and dietary habits, and genetic 
components affect the risk of developing DM. 66 These factors are more clearly defined for 
type 2 DM. Obesity is a major risk factor, and 80–90% of type 2 DM subjects in the U.S. 
are obese. Studies also support a strong genetic basis for type 2 DM. Mutations in 
glucokinase cause the autosomal dominant disorder MODY2; these patients have an 
increased glycemic threshold for insulin release that results in persistent mild 
hyperglycemia. Other single-gene mutations cause the other types of MODY, including 
those affecting pancreatic transcription factors. 64 
Obesity and insulin resistance 66 
                    Insulin resistance is defined as the failure of the target tissues to respond 
normally to insulin. It leads to decreased uptake of glucose in muscle, reduced glycolysis 
and fatty acid oxidation in the liver, and an inability to suppress hepatic gluconeogenesis. 
                    The epidemiologic association of obesity with Type 2 diabetes has recognised 
for decades, with visceral obesity observed in greater than 80% of patients. Obesity has 
profound effects on sensitivity of tissues on insulin and as a consequence, on systemic 
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glucose homeostasis. Insulin resistance is present even in simple obesity unaccompanied 
by hyperglycemia, indicating a fundamental abnormality of insulin in state of fat excess. 
The risk of diabetes increases as the body mass index increases. It is not the absolute 
amount but also the distribution of body fat that has effect on insulin sensitivity: central 
obesity (abdominal fat) is more likely to be linked with insulin resistance than are 
peripheral fat depots. 
 
β -Cell Dysfunction 
                    In type 2 diabetes, β cells seemingly exhaust their capacity to adapt to the 
long term demands of peripheral insulin resistance. In states of insulin resistance like 
obesity, insulin secretion is initially higher for each level of glucose than in controls. This 
hyperinsulinemic state is a compensation for peripheral resistance and can often maintain 
normal plasma glucose for years. Eventually, however, β cells compensation becomes 
inadequate and there is a progression of hyperglycemia. The observation is that not all the 
obese individuals with insulin resistance develop overt diabetes suggests that an intrinsic 
predisposition to β cell failure must also exist. 
 
Fig. 10: Long-term complications of Diabetes 
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Morphology of diabetes and its late complications 
               Pathologic findings in the pancreas are variable and not necessarily dramatic. 
The important morphologic changes are related to many late systemic complications of 
diabetes. 
1. Pancreas: Lesions in the pancreas are inconstant and rarely of diagnostic value. 
Distinctive changes are more commonly associated with type 1 than with type 2 
diabetes. One or more of the following alterations may be present. 
• Reduction in the number and size of islets. 
• Leukocytic infiltrates in the islets. 
• Subtle reduction in islet cell mass in Type 2 diabetes 
• Amyloid deposition within islets in Type 2 diabetes 
• An increase in the number and size of islets 
2. Diabetes Macrovascular disease: Diabetes exacts a heavy toll on the vascular 
system. Endothelial dysfunction which predisposes to atherosclerosis and other 
cardiovascular morbidities is widespread in diabetes, as a consequence of the 
deleterious effect of persistent hyperglycemia and insulin resistance on the vascular 
compartment. Myocardial infarction caused by atherosclerosis of the coronary arteries, 
is the most common cause of death in diabetes. 
3. Hyaline arteriosclerosis 
4. Diabetic Microangiopathy 
5. Diabetic Nephropathy 
6. Renal atherosclerosis and arteriosclerosis 
7. Pyelonephritis 
8. Diabetic ocular complications 
9. Diabetic Neuropathy 
 
Clinical features of diabetes mellitus 67, 68 
 Polyuria, polydipsia, and polyphagia 
 Weight loss and irreducible fatigue. 
 Blurred vision 
 Decreased sensation or numbness in the hands and feet 
 Dry, itchy skin 
 Profiles 
 
Department of Pharmaceutics, Madras Medical College Page 37 
 
 Frequent bladder and vaginal infections 
 male impotence (erectile dysfunction) 
 slow healing of cuts or sores  
 Family history of diabetes (i.e., parent or sibling with type 2 diabetes) 
 Obesity (BMI _ 25 kg/m2) 
  Habitual physical inactivity 
  Race/ethnicity (e.g., African American, Hispanic American, Native 
                    American, Asian American, Pacific Islander) 
 Previously identified IFG or IGT 
 History of GDM or delivery of baby >4 kg (>9 lb) 
  Hypertension (blood pressure ≥140/90 mmHg) 
  HDL cholesterol level ≤ 35 mg/dL (0.90 mmol/L) and/or a triglyceride 
                 Level ≥250 mg/dL (2.82 mmol/L) 
    Polycystic ovary syndrome or Acanthosis nigracans 
   History of vascular disease 
 
Unfortunately, many people with type 2 diabetes go undiagnosed for several years 
and are not diagnosed until they go to the doctor with symptoms or complications of 
diabetes. 
Diagnosis 
                  Blood glucose values are normally maintained in a very narrow range, usually 
70 to 120 mg/dL. The diagnosis of diabetes is established by noting elevation of blood 
glucose by any of the three criteria. 
i. A random glucose concentration greater than 200mg/dL, with classical signs and 
symptoms.  
ii. A fasting glucose concentration greater than 126mg/dL on more than one occasion. 
iii. An abnormal oral glucose tolerance test (OGTT), in which the glucose 
concentration is greater than 200mg/dL 2hours after a standard carbohydrate load  
 
 
 
 
 Profiles 
 
Department of Pharmaceutics, Madras Medical College Page 38 
 
Treatment and Management 62 
  The main goal of diabetes management is to maintain blood glucose levels 
within the normal range as much as possible. Weight control, diet, and exercise are all 
important components of management. The most important and main treatment for type 2 
diabetes is nutritional. 
 Weight reduction and exercise  
 Treatment with insulin analogues (for Type I diabetes) 
 Treatment with oral hypoglycaemic agents (for Type II diabetes) 
 There are several types of oral diabetes medications, also called oral 
hypoglycemics, which work to lower blood glucose: 
 Sulfonylureas: This family of medications includes Gliclazide, Glimepiride, and 
Glyburide. These medications are widely recommended for type 2 diabetes and 
work by stimulating the pancreas to release insulin. However, these medications 
don't work for type 1 diabetes. 
 Biguanides: This medications include Metformin and work to improve insulin 
sensitivity and to reduce the glucose produced by the liver. 
 Acarbose: This type of medication prolongs the absorption of carbohydrates after 
a meal. For these pills to work, they must be taken with or after a meal. 
 Thiazolidinediones: This family of medications includes Pioglitazone and 
Rosiglitazone and they work to improve insulin sensitivity. 
 Meglitinides: This family of medications includes Repaglinide and Nateglinide. 
They lower postprandial (after meals) glucose levels by stimulating the pancreas to 
release insulin. 
 Dipeptidyl peptidase-4 inhibitors: This class of medications includes Sitagliptin 
and saxagliptin. They help improve insulin release from the pancreas and decrease 
liver release of glucose. 
 GLP-1 analogs: This class of medications includes Liraglutide, which is a 
synthetic form of the hormone GLP-1. It helps the body release insulin when blood 
sugar levels are high, and also reduces the release of sugar from the liver. It is 
taken as a daily injection under the skin. 
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Disease Profile 
        Hypertension 69, 70 
  Hypertension is defined as sustained elevation of systemic arterial blood 
pressure. Blood pressure is the force, which the blood put against the walls of arteries as it 
flows through them. Arteries are the blood vessels that carry oxygenated blood from the 
heart to the body’s tissues. 
   BP = Cardiac output X Peripheral resistance 
 
CLASSIFICATION  
1. Primary hypertension 
                  They also called as essential or idiopathic hypertension, affects 90% to 95% of 
hypertensive individuals.  
2. Secondary hypertension 
  It is caused by altered hemodynamics associated with primary disease, such as 
renal disease. Although many diseases cause secondary hypertension, this forms of 
hypertension accounts of 5% to 8% of cases. 
3. Isolated hypertension 
  It is elevated systolic blood pressure accompanied by normal diastolic blood 
pressure (below 90mmHg). It is the manifestation of increased cardiac output or rigidity of 
aorta or both. 
 
RISK FACTORS 
 FOR PRIMARY HYPERTENSION 
• Family history 
• Advancing age 
• Race (most common in blacks) 
• Obesity 
• Tobacco use 
• High intake of sodium or saturated fat 
• Excessive alcohol consumption 
• Sedentary lifestyle, stress. 
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 FOR SECONDARY HYPERTENSION 
• Excessive Renin 
• Mineral deficiencies (calcium, potassium& magnesium) 
• Diabetes mellitus 
• Coarctation of the aorta 
• Renal artery disease or parenchymal disease 
• Brain tumor, quadriplegia, head injury 
• Pheochromocytoma, Cushing’s syndrome, Hyperaldosteronism 
• Thyroid, pituitary or parathyroid dysfunction  
• Hormonal contraceptive, cocaine, sympathetic stimulants, MAO inhibitors 
taken with tyramine, oestrogen replacement therapy, NSAID’s 
• Pregnancy 
 
PATHOPHYSIOLOGY 
                         Arterial blood pressure is a product of total peripheral resistance and 
cardiac output. Cardiac output is increased by conditions that increase heart rate or stroke 
volume, or both. Peripheral resistance is increased by factors that increase blood viscosity 
or reduce the lumen size of vessels. 
           Several mechanisms may lead to hypertension, including 
 Changes in the arteriolar bed causing increased peripheral vascular resistance 
 Abnormally increases tone in the sympathetic nervous system that originates in the 
vasomotor system centres, causing increased peripheral vascular resistance. 
 Increased blood volume resulting from renal or hormonal dysfunction 
 Arteriolar thickening caused by genetic factors, leading to increased peripheral 
vascular resistance. 
 Abnormal renin release, resulting in the formation of Angiotensin II, which 
constricts the arteriole and increased blood volume. 
                        Prolonged hypertension increases the workload of the heart as resistance to 
left ventricular ejection increases. To increase contractile force, the left ventricle 
hypertrophies, raising the oxygen demand and workload of the heart. 
                        The pathophysiology of secondary hypertension is related to the underlying 
disease. 
 Profiles 
 
Department of Pharmaceutics, Madras Medical College Page 41 
 
 Stroke 
 Myocardial infarction 
 Heart failure 
 Arrhythmias  
 Retinopathy  
 Encephalopathy  
 Renal failure 
 
SIGNS AND SYMPTOMS 63 
i. Generally produces no symptoms 
ii. Occipital headache 
iii. Epistaxis possibility due to vascular environment 
iv. Bruits 
v. Dizziness, confusion, fatigue 
vi. Blurry vision 
vii. Nocturia 
viii. Edema 
 
DIAGNOSTIC TEST RESULTS 
 Serial blood pressure measurements show elevation 
 Urine analysis shows protein, casts, red blood cells or white blood cells suggesting 
renal disease; presence of catecholamines associated with pheochromocytoma; or 
glucose, suggesting diabetes 
 Blood chemistry reveals elevated blood urea nitrogen and serum creatinine levels 
suggestive of renal disease or hypokalemia indicating adrenal dysfunction. 
 Excretory urography may reveal renal atrophy, indicating chronic renal disease. 
 Electrocardiography detects left ventricular hypertrophy or ischemia. 
 Chest X-rays shows cardiomegaly. 
 Echocardiography reveals left ventricular hypertrophy. 
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TREATMENT 
1. Lifestyle modifications to reduce risk factors  
2. Treatment of underlying cause 
3. Treatment with antihypertensive agents 62 
The various agents used are 
01. ACE inhibitors 
Captopril, Enalapril, Lisinopril, Perindopril, Ramipril. 
02. Angiotensin (AT1) Antagonists 
Losartan, candesartan, Irbesartan, Olmesartan 
03. Calcium channel blockers 
Verapamil, Diltiazem, Nifedipine, Felodipine, Amlodipine, Nitrendipine, 
Lacidipine 
04. Diuretics  
i)   Thiazides : Hydrochlorothiazide, chlorthalidone, Indapamide 
ii)  High ceiling : Furosemide 
iii) Potassium sparing : Spironolactone, Triamterene, Amiloride 
05. β Adrenergic Blockers 
Propranalol, Metoprolol, Atenolol 
06. Β +α Adrenergic Blockers 
Labetolol, Carvedilol 
07. α Adrenergic Blockers 
Prazosin, Terazosin, Doxazosin, Phentolamine, Phenoxybenzamine 
08. Central sympatholytics 
Clonidine, Methyldopa 
09. Vasodilators 
i) Arteriolar : Hydralazine, Minoxidil, Diazoxide 
ii) Arteriolar + Venous: Sodium Nitroprusside.     
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LOSARTAN POTASSIUM
Chemical structure  
 
Chemical Name  
 
                                                             
Molecular Formula  
Molecular Weight  
Description                                  
Solubility                            
 
 
DRUG PROFILE 
 
71, 72
 
 
 :     Monopotassium salt of 2-butyl 4 chloro
        [[2’-(1H-tetrazol-5-yl)[1,1’- biphenyl]
Methyl] 1H-imidazole-5-methanol.
      :     C22H22ClKN6O 
      :     461.0 
 :    A white to off- white crystalline powder.
  :   Freely soluble in water, soluble in alcohols, 
    slightly soluble in common organic
    solvents such as Acetonitrile and methyl 
    ethyl ketone. 73 
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Mechanism of Action  
    Losartan is the first of a class of antihypertensive agents called Angiotensin II 
(AG II) receptor antagonists. It is, along with its longer acting active metabolite (E-3174), a 
specific and selective AT1 receptor antagonist. Losartan blocks the vasoconstrictor and 
aldosterone-secreting effects of Angiotensin II by selectively blocking the binding of 
Angiotensin II to the AT1 receptor found in many tissues, (e.g., vascular smooth muscle, 
adrenal gland). 
   Losartan and its longer acting active metabolite (E-3174) interfere with the 
binding of Angiotensin II to AT1-receptor including vascular smooth muscle and the adrenal 
glands. As Angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release 
of Aldosterone, blockage of its effects results in decrease in systemic vascular resistance. 
Neither Losartan nor its metabolite inhibits the Angiotensin converting enzyme, other 
hormone receptors, or ion channels. 
 
     Pharmacokinetics 62 
 
Absorption   :    Absorbed well orally but undergoes substantial 
                 first pass metabolism. 
Bioavailability   :     Approximately 33%   
Half life    :     The terminal t1/2 of Losartan is 2.5 hours and  
          that of E-3174(active metabolite) is 6-9 hours. 
Plasma Protein binding   :     99.7%, primarily to albumin. 
Volume of distribution    :     34 L [Losartan], 12 L [active metabolite]. 
          Metabolism             :    The metabolism of Losartan to E -3174 and to  
                                             inactive metabolites is mediated by CYP2C9 
                                                                         and CYP3A4. 
         Excretion               :     4% is excreted in unchanged form, 6% of active  
                                                                         Metabolite is excreted in urine. Biliary excretion 
                                                Contributes to the elimination of Losartan and its  
                                                                         metabolites.  
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 Therapeutic Indications 
1. Treatment of hypertension - given alone or in combination with other antihypertensive 
agents. 
2. Nephropathy in Type 2 Diabetic patients. 
Route/Dosage 
1. Hypertension: 
Adults: PO Initial dose: 50 mg once/day; 25 mg once/day if volume depleted or history of 
hepatic impairment. Maintenance: 25 to 100 mg/day. 
2. Nephropathy in Type 2 Diabetes: 
Adults: PO Initial dose: 50 mg once daily; the dose may be increased to 100 mg once daily 
based on BP response. 
Contraindications:   Hypersensitivity to Losartan potassium. 
Adverse effects     : Dizziness, insomnia, nasal congestion, diarrhoea, dyspepsia, sinusitis, 
muscle cramps, myalgia, back pain, leg pain. 
Drug interactions 
01. Losartan may increase levels of blood potassium which can lead to serious heart 
problems (arrhythmias). Therefore, concomitant use of other substances that increase 
blood potassium-such as potassium-sparing diuretics (for example, spironolactone , 
triamterene, and amiloride), potassium supplements, or salt substitutes containing 
potassium, may lead to dangerous increases in serum potassium. 
02. Combining losartan or other ARBs with Nonsteroidal Anti-Inflammatory Drugs 
(NSAIDs) in patients who are elderly, volume-depleted (including those on diuretic 
therapy), or with poor kidney function may result in reduced kidney function, 
including kidney failure. These effects usually are reversible. The antihypertensive effect 
of losartan may be reduced by aspirin and other NSAIDs such 
as ibuprofen, indomethacin  and naproxen. 
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METFORMIN HYDROCHLORIDE 74, 75 
Chemical structure   
 
 
Chemical Name   :  1,1 Dimethylbiguanide monohydrochloride 
Molecular Formula   :  C4H11N5.Hcl 
Molecular Weight   :  165.62 
Description    :  A white, hygroscopic, crystalline powder. 
Solubility                       :  Freely soluble in water, soluble in ethanol, practically  
                                                         insoluble in chloroform and ether. 
Mechanism of Action  
                 The mechanism of action of Metformin hydrochloride is different from other 
classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, 
decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing 
peripheral glucose uptake and utilization. These effects are mediated by the initial activation 
by Metformin of AMP-activated protein kinase (AMPK), a liver enzyme that plays an 
important role in insulin signalling, whole body energy balance, and the metabolism of 
glucose and fats. Activation of AMPK is required for Metformin's inhibitory effect on the 
production of glucose by liver cells. Increased peripheral utilization of glucose may be due to 
improved insulin binding to insulin receptors. AMPK probably also plays a role, as 
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Metformin administration increases AMPK activity in skeletal muscle. AMPK is known to 
cause GLUT4 deployment to the plasma membrane, resulting in insulin independent glucose 
uptake.                                  
Pharmacokinetics 62 
     
Absorption       :   Metformin is absorbed mainly from the small intestine. 
Bioavailability     :   50 to 60% under fasting conditions.  
Half life        :   ~2 hours. 
Plasma protein binding     :  The drug is stable, does not bind to plasma proteins. 
Metabolism          :   It is not metabolized. 
Excretion                                 :   Excreted unchanged in the urine.  
 
Therapeutic indications 
01. For use as an adjunct to diet and exercise to improve glycemic control in adult patients 
(18 years and older) with type 2 diabetes. 
02. Prediabetes. 
03. Polycystic ovary syndrome. 
04. Gestational diabetes. 
 
 Route/Dosage 
             The maximum recommended daily dose of Metformin is 2.5 g divided into three 
doses with meals. 
 
Contraindications 
              Renal disease or dysfunction as suggested by serum Creatinine > 1.5 mg/dL in males 
or > 1.4 mg/dL in females or abnormal Ccr; conditions which predispose to renal dysfunction 
(eg, cardiovascular collapse, acute MI, septicaemia); in patients undergoing radiologic studies 
involving parenteral administration of iodinated contrast material (potential to acutely alter 
renal function); acute or chronic metabolic acidosis, including diabetic ketoacidosis. 
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Adverse effects 
         Unpleasant/metallic taste, Diarrhea, nausea, vomiting, abdominal bloating, flatulence, 
anorexia, Lactic acidosis, subnormal vitamin B12 levels. 
 
Drug interactions 
1.  Alcohol: Potentiates effect of Metformin on lactate metabolism. 
2. Cationic Drugs (eg, Amiloride, Digoxin, Quinidine): May increase Metformin serum                      
concentration by competing for tubular secretion. 
3. Cimetidine: Increases Metformin serum concentration. 
4. Furosemide: May increase Metformin serum concentration; Metformin may reduce 
furosemide serum concentration. 
5. Iodinated Contrast Material: May cause acute renal failure and has been associated with   
lactic acidosis in patients receiving Metformin. 
6. Nifedipine: Increases Metformin serum concentration. 
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 EXCIPIENT PROFILE 
LACTOSE 76 
 
1. Nonproprietary Names 
               BP: Lactose, PhEur: Lactose Monohydrate, USP-NF: Lactose monohydrate 
2. Synonyms 
CapsuLac; GranuLac; Lactochem; Lactosum monohydricum Monohydrate; 
Pharmatose; PrismaLac; SacheLac; SorboLac; SpheroLac; SuperTab 30GR; Tablettose. 
3. Chemical Name  
               O-β-D-Galactopyranosyl-(1, 4)-α-D-glucopyranose monohydrate 
4. Empirical Formula 
              C12H22O11. H2O  
5. Molecular Weight 
               360.31 
6. Functional Category 
Dry powder inhaler carrier, lyophilization aid, tablet binder, tablet and capsule 
diluents, tablet and capsule filler. 
7. Description 
The stable crystalline forms of lactose are α-lactose monohydrate, β-lactose 
anhydrous and stable α-lactose anhydrous. Lactose occurs as white to off-white crystalline 
particles or powder. Lactose is odorless and slightly sweet-tasting, α-lactose is approximately 
20% as sweet as sucrose, while β-lactose is 40% as sweet. 
8. Solubility 
 Practically insoluble in chloroform, ethanol and ether. Soluble in water. 
9. Applications 
Lactose is widely used as filler and diluent in tablets and capsules. Lactose is also 
used as a diluent in dry-powder inhalation; Lactose is also used in the manufacture of dry 
powder formulations for use as aqueous film-coating solutions or suspensions. Lactose is also 
used in combination with sucrose (approximately 1:3) to prepare sugar-coating solutions. 
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HYDROXYPROPYLMETHYL CELLULOSE 76 
 
1. Nonproprietary Names 
              BP:Hypromellose, JP: Hypromellose, PhEur: Hypromellose, USP: Hypromellose 
2. Synonyms 
               Benecel MHPC; E464; Hydroxy propyl methylcellulose;HPMC; hypromellosum; 
Methocel; methycellulose propylene glycol ether; methyl hydroxypropylcellulose; Metolose; 
MHPC; Pharmacoat; Tylopur; Tylose. 
3. Chemical Name 
               Cellulose hydroxypropyl methyl ether 
4. Molecular Weight 
               Molecular weight is approximately 10000–1500000. 
5. Functional Category 
          Bio-adhesive material, coating agent, controlled-release agent, emulsifying agent, 
film-forming agent, suspending agent, sustained-release agent and tablet binder. 
6. Description 
               Hypromellose is an odourless and tasteless, white or creamy-white fibrous or 
granular powder. 
7. Solubility 
               Soluble in cold water, forming a viscous colloidal solution; practically insoluble in 
hot water, chloroform, ethanol (95%) and ether. 
8. Incompatibilities 
               Hypromellose is incompatible with some oxidizing agents. 
9. Applications 
               Hypromellose is widely used in oral, ophthalmic, nasal, and topical pharmaceutical 
formulations. It is primarily used as a tablet binder, in film-coating and as a matrix for use in 
extended release tablet formulations. Concentrations between 2-5% w/w may be used as a 
binder in either wet or dry granulation processes. High-viscosity grades may be used to retard 
the release of drugs from a matrix at levels of 10–80% w/w in tablets and capsules. 
Hypromellose is also used in liquid oral dosage forms as a suspending and/or thickening agent 
at concentrations ranging from 0.25–5.0%. 
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ETHYLCELLULOSE 76 
1. Nonproprietary Names 
               BP: Ethylcellulose, PhEur: Ethylcellulose, USP-NF: Ethylcellulose 
2.  Synonyms 
               Aquacoat ECD; Aqualon; Ashacel; E462; Ethocel; ethylcellulosum; Surelease. 
3.  Chemical Name  
               Cellulose ethyl ether 
4.  Empirical Formula and Molecular Weight 
               Ethylcellulose is partially ethoxylated. Ethylcellulose with complete ethoxyl 
substitution (DS = 3) is C12H23O6 (C12H22O5) nC12H23O5 where n can vary to provide a wide 
variety of molecular weights. 
5.  Functional Category 
               Coating agent, tablet binder, tablet filler, viscosity increasing agent. 
6. Description 
               Ethylcellulose is a tasteless, free-flowing, white to light tan-coloured powder. 
7. Solubility 
               Ethylcellulose is practically insoluble in glycerin, propylene glycol, and water. 
8. Incompatibilities 
               Incompatible with paraffin wax and microcrystalline wax. 
9. Applications 
              Ethylcellulose is widely used in oral and topical pharmaceutical formulations. The 
main use of ethyl cellulose in oral formulations is as a hydrophobic coating agent for tablets 
and granules. Ethylcellulose coatings are used to modify the release of a drug, to mask an 
unpleasant taste, or to improve the stability of a formulation. High-viscosity grades of ethyl 
cellulose are used in drug microencapsulation. High-viscosity grades of ethyl cellulose are 
used in drug microencapsulation. Ethylcellulose has also been used as an agent for delivering 
therapeutic agents from oral (e.g. dental) appliances. In topical formulations, ethylcellulose is 
used as a thickening agent in creams, lotions, or gels, provided an appropriate solvent is used. 
Ethyl cellulose is additionally used in cosmetics and food products. 
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EMICROCRYSTALLINE CELLULOSE 76 
1.  Nonproprietary Names 
               BP: Microcrystalline Cellulose, JP: Microcrystalline Cellulose, PhEur: Cellulose, 
Microcrystalline, USP-NF: Microcrystalline Cellulose. 
2. Synonyms 
              Avicel PH; Cellets; Celex; cellulose gel; hellulosum microcristallinum; Celphere; 
Ceolus KG; crystalline cellulose; E460; Emcocel;Ethispheres; Fibrocel; MCC Sanaq; 
Pharmacel; Tabulose; Vivapur. 
3.  Chemical Name 
              Cellulose  
4.  Empirical Formula  
               (C6H10O5) n where n = 220. 
5.  Functional Category 
              Tablet and capsule diluent, Adsorbent, tablet disintegrant, suspending agent.                                    
6.  Description 
              Microcrystalline cellulose is purified, partially depolymerised cellulose that occurs as 
a white, odorless, tasteless, crystalline powder composed of porous particles. It is 
commercially available in different particle sizes and moisture grades that have different 
properties and applications. 
7. Solubility 
              Slightly soluble in 5% w/v sodium hydroxide solution; practically insoluble in water, 
dilute acids, and most organic solvents. 
8. Incompatibilities 
             Microcrystalline cellulose is incompatible with strong oxidizing agents. 
9. Applications 
             Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet-granulation 
and direct-compression processes. In addition to its use as binder/diluents, microcrystalline 
cellulose also has some lubricant and disintegrant properties that make it useful in tabletting. 
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STARCH 76 
 
1. Nonproprietary Names 
              BP: Maize starch, Potato starch, Rice Starch, Tapioca Starch, Wheat Starch JP: Corn 
Starch, Potato Starch Rice Starch, Wheat Starch, PhEur: Maize Starch, Pea Starch, Potato 
Starch, Rice Starch, Wheat Starch USP-NF: Corn Starch, Potato Starch, Tapioca Starch, 
Wheat Starch 
2.  Synonyms 
              Amido; amidon; amilo; amylum; C*PharmGel; Eurylon; fecule;Hylon; maydis 
amylum; Melojel; Meritena; oryzae amylum; Pearl;Perfectamyl; pisi amylum; Pure-Dent; 
Purity 21; Purity 826; solani amylum; tritici amylum. 
3.  Chemical Name 
                     Starch  
4.  Empirical Formula 
              (C6H10O5) n where n = 300–1000. 
5.  Functional Category 
              Tablet and capsule diluent, tablet and capsule disintegrant, tablet binder, thickening 
agent. 
6. Description 
              Starch occurs as an odorless and tasteless, fine, white to off-white powder. 
7. Solubility 
             Practically insoluble in cold ethanol (96%) and in cold water Starch becomes soluble 
in hot water at temperatures above the gelatinization temperature. Starches are partially 
soluble in dimethylsulfoxide and dimethylformamide. 
8. Applications 
            Starch is a versatile excipient used primarily in oral solid-dosage formulations where it 
is utilized as a binder, diluent, and disintegrant. In tablet formulations, freshly prepared starch 
paste is used at a concentration of 3–20% w/w (usually 5–10%, depending on the starch type) 
as a binder for wet granulation. Starch is one of the most commonly used tablet disintegrants 
at concentrations of 3–25% w/w; a typical concentration is 15%. Starch has been investigated 
as an excipient in novel drug delivery systems for nasal and other site-specific delivery 
systems. 
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SODIUM STARCH GLYCOLATE 76 
 
1. Nonproprietary Names 
            BP: Sodium Starch Glycolate, PhEur: Sodium Starch Glycolate,   USP-NF: Sodium 
Starch Glycolate. 
2.  Synonyms 
             Carboxy methyl starch, sodium salt; carboxy methyl amylum natricum; Explosol: 
Explotab; Glycolys; Primojel; starch carboxy methyl ether, sodium salt; Tablo; Vivastar P. 
3. Chemical Name 
               Sodium carboxymethyl starch. 
4. Functional Category 
           Tablet and capsule disintegrant. 
5. Description 
           Sodium starch glycolate is a white or almost white free-flowing very hygroscopic 
powder. 
6. Solubility 
          Practically insoluble in methylene chloride. It gives a translucent suspension in water. 
7. Applications 
          Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant in 
capsule and tablet formulations. It is commonly used in tablets prepared by either direct-
compression or wet-granulation processes. The usual concentration employed in a formulation 
is between 2% and 8%, with the optimum concentration of about 4%. Disintegration occurs 
by rapid uptake of water followed by rapid and enormous swelling. Increasing the tablet 
compression pressure also appears to have no effect on disintegration time. 
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POVIDONE 76 
 
1.  Nonproprietary Names   
      BP: Povidone, PhEur: Povidone, USP-NF: Povidone. 
2.  Synonyms 
            E1201; Kollidon; Plasdone; poly[1-(2-oxo-1-pyrrolidinyl)ethylene]; polyvidone; 
polyvinylpyrrolidone; povidonum; Povipharm; PVP; 1- vinyl-2-pyrrolidinone polymer. 
3.  Chemical Name 
           1-Ethenyl-2-pyrrolidinone homopolymer 
4. Empirical Formula 
            (C6H9NO) n  
5. Molecular Weight 
            2500–3,000,000 
6. Functional Category 
            Disintegrant, dissolution enhancer, suspending agent, tablet binder. 
7.  Description 
            Povidone occurs as a fine, white to creamy-white colored, odourless or almost 
odorless, hygroscopic powder. Povidones with K-values equal to or lower than 30 are 
manufactured by spray-drying and occur as spheres. Povidone K-90 and higher K-value 
povidones are manufactured by drum drying and occur as plates. 
8. Solubility 
            Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol and water.  
Practically insoluble in ether, hydrocarbons and mineral oil. 
9. Applications 
            Povidone is used in a variety of pharmaceutical formulations primarily used in solid-
dosage forms. In tabletting, Povidone solutions are used as binders in wet-granulation 
processes. It is also added to powder blends in the dry form and granulated in situ by the 
addition of water, alcohol, or hydro alcoholic solutions. Povidone is used as a solubilizer in 
oral and parenteral formulations, and has been shown to enhance dissolution of poorly soluble 
drugs from solid-dosage forms Povidone is also used as a suspending, stabilizing, or 
viscosity-increasing agent in a number of topical and oral suspensions and solutions.  
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MAGNESIUM STEARATE 76 
 
1. Nonproprietary Names 
            BP: Magnesium Stearate, JP: Magnesium Stearate, PhEur: Magnesium Stearate USP-
NF: Magnesium Stearate. 
2. Synonyms 
            Dibasic magnesium stearate; magnesium distearate; magnesia stearas; magnesium 
octadecanoate; octadecanoic acid, magnesium salt; stearic acid, magnesium salt; Synpro 90. 
3.  Chemical Name 
            Octadecanoic acid magnesium salt  
4.  Empirical Formula  
            C36H70MgO4 
5. Molecular Weight 
            591.24 
6. Functional Category 
            Tablet and capsule lubricant. 
7. Description 
            Magnesium stearate is a very fine, light white, impalpable powder of low bulk density, 
having a faint odour of stearic acid and a characteristic taste. The powder is greasy to the 
touch and readily adheres to the skin. 
8. Incompatibilities 
            Incompatible with strong acids, alkalis, and iron salts. 
9. Applications 
            Magnesium stearate is widely used in cosmetics, foods and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. Magnesium stearate is hydrophobic and may 
retard the dissolution of a drug from a solid dosage form; the lowest possible concentration is 
therefore used in such formulations. It is also used in barrier creams. 
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TALC 76 
 
1.  Nonproprietary Names 
            BP: Purified Talc, JP: Talc, PhEur: Talc, USP: Talc 
2.  Synonyms 
            Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium silicate; 
Imperial; Luzenac Pharma; magnesium hydrogen metasilicate; Magsil smanthus; Magsil Star; 
powdered talc; purified French chalk; Purtalc; soapstone; steatite; Superiore; talcum. 
3.  Chemical Name 
            Talc  
4.  Empirical Formula 
            Talc is a purified, hydrated, magnesium silicate, approximating to the formula Mg6 
(Si2O5)4 (OH)4. It may contain small, variable amounts of aluminium silicate and iron. 
5. Functional Category 
             Anticaking agent, glidant, tablet and capsule diluent; tablet and capsule lubricant. 
6. Description 
            Talc is a very fine, white to greyish-white, odorless, impalpable, crystalline powder. It 
adheres readily to the skin and is soft to the touch and free from grittiness. 
7. Solubility 
            Practically insoluble in dilute acids and alkalis, organic solvents, and water. 
8. Incompatibilities 
            Incompatible with quaternary ammonium compounds. 
9. Applications 
            Talc was widely used in oral solid dosage formulations as a lubricant and diluent. It is 
widely used as a dissolution retardant in the development of controlled-release products. Talc 
is also used as a lubricant in tablet formulations in a novel powder coating for extended-
release pellets and as an adsorbent. In topical preparations, talc is used as a dusting powder. 
Talc is additionally used to clarify liquids and is also used in cosmetics and food products, 
mainly for its lubricant properties. 
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ACETONE 76 
 
1.  Nonproprietary Names 
            BP: Acetone, PhEur: Acetone, USP-NF: Acetone. 
2. Synonyms 
            Acetonum; dimethylformaldehyde; dimethyl ketone; b-ketopropane; pyroacetic ether.   
3. Chemical Name 
            2-Propanone  
4. Empirical Formula  
            C3H6O  
5. Molecular Weight 
             58.08 
6. Functional Category 
             Solvent 
7.  Description 
             Acetone is a colorless, volatile, flammable, transparent liquid, with a sweetish odour 
and pungent sweetish taste. 
8. Solubility 
             Soluble in water; freely soluble in ethanol (95%). 
9.  Incompatibilities 
             Acetone reacts violently with oxidizing agents, chlorinated solvents, and alkali 
mixtures. It reacts vigorously with sulphur dichloride, potassium t-butoxide and 
hexachloromelamine. Acetone should not be used as a solvent for iodine, as it forms a volatile 
compound that is extremely irritating to the eyes. 
10. Applications 
              Acetone is used as a solvent or co solvent in topical preparations, and as an aid in wet 
granulation. It has also been used when formulating tablets with water-sensitive active 
ingredients, or to solvate poorly water-soluble binders in a wet granulation process. Acetone 
has also been used in the formulation of microspheres to enhance drug release. Owing to its 
low boiling point, acetone has been used to extract thermolabile substances from crude drugs. 
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ISOPROPYL ALCOHOL 76 
 
1.  Nonproprietary Names 
             BP: Isopropyl Alcohol, JP: Isopropanol, PhEur: Isopropyl Alcohol, USP: Isopropyl 
Alcohol 
2. Synonyms 
             Alcohol isopropylicus; dimethyl carbinol; IPA; isopropanol; petrohol; 2-propanol; 
sec-propyl alcohol; rubbing alcohol. 
3. Chemical Name 
             Propan-2-ol  
4.  Empirical Formula 
             C3H8O  
5. Molecular Weight 
             60.1 
6. Functional Category 
             Disinfectant, solvent. 
7. Description 
             Isopropyl alcohol is a clear, colorless, mobile, volatile, flammable liquid with a 
characteristic, spirituous odour resembling that of a mixture of ethanol and acetone; it has a 
slightly bitter taste.  
8. Solubility 
             Miscible with benzene, chloroform, ethanol (95%), ether, glycerin, and water.  
9. Incompatibilities 
             Incompatible with oxidizing agents such as hydrogen peroxide and nitric acid, which 
cause decomposition. 
10. Applications 
             Isopropyl alcohol (propan-2-ol) is used in cosmetics and pharmaceutical 
formulations, primarily as a solvent in topical formulations, Although it is used in lotions, the 
marked degreasing properties of isopropyl alcohol may limit its usefulness in preparations 
used repeatedly. Isopropyl alcohol is also used as a solvent both for tablet film-coating and for 
tablet granulation, where the isopropyl alcohol is subsequently removed by evaporation. 
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6. MATERIALS AND METHODS 
Table 1:List of materials and their applications in formulation. 
S.No Name of the material Manufacture/ Supplier Use in formulation 
1. Metformin hydrochloride 
Abhilash Chemicals, Tamilnadu, 
India 
Active ingredient 
2. Losartan potassium 
Synergene Active Ing. (P) Ltd, 
Hyderabad, India 
Active  ingredient 
3. HPMC K4M Samsung fine chemicals, Korea Hydrophilic polymer 
4 HPMC K100M Samsung fine chemicals, Korea Hydrophilic polymer 
5. Ethyl cellulose Zhongbao chemicals, China 
Non swellable 
polymer 
6. Microcrystalline cellulose Vikaas Chemical, Chennai Diluent 
7. Lactose Saputo, Montreal Quebec, Canada Diluent 
8. Starch Reddy’s Pharm, New Delhi Diluent 
9. Sodium starch glycolate JR Pharm, Chatrang Superdisintegrant 
10 
Poly vinyl pyrrolidone 
K30 
Jiao Zuo Yuanhai Fine Chemicals 
Ltd., China 
Binder 
11. Isopropyl alcohol 
Deepak Fertilizers and 
petrochemicals, Pune, India 
Solvent 
12. Acetone 
Deepak Fertilizers and 
petrochemicals, Pune, India 
Solvent 
13. Talc S D fine chemicals, Mumbai Glidant 
14. Magnesium stearate Zudila Enterprise, China Lubricant 
15. Tartrazine yellow 
Neelikon food dyes & Chemicals, 
Mumbai, India 
Colouring agent 
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Table 2: List of Equipments/Instruments used 
S.No Equpiments/ Instruments Manufacture/ Supplier 
1. Electronic weighing balance Shimadzu, Japan 
2. Tray Drier Chitra, Ahmedabad 
3. Hot Air Oven Industrial heaters, Chennai 
4. 27 Station Rotary Compression Machine Cadmach, Ahmedabad 
5. 27 Station Rotary Bilayer Compression Machine Cadmach, Ahmedabad 
6. Vernier calliper Mitutoyo, Japan 
7. Monsanto Hardness Tester Erweka, Mumbai 
8. Friabilator Electrolab, India 
9. pH Meter Symchrony, India 
10. Sonicator Leela electronics, Chennai 
11. Disintegration Apparatus Veego, Mumbai 
12. Dissolution Apparatus Veego, Mumbai 
13. UV- Visible Spectrophotometer Shimadzu, Japan 
14. Fourier Transform Infra Red Spectrophotometer Nicolet, India 
15. Stability Chamber Technico, India 
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METHODOLOGY 
PREFORMULATION STUDIES 77 
              Preformulation study is the first step in the rational development of dosage forms 
of a drug substance. It can be defined as an investigation of physical and chemical 
properties of a drug substance alone and when combined with excipients. The overall 
objective of preformulation studies is to generate information useful to the formulator in 
developing stable and bioavailable dosage forms that can be mass produced. 
 
DRUG EXCIPIENT COMPATIBILITY STUDY 
              The drug and the excipients chosen for the formulation were screened for 
compatibility by physical methods and Fourier Transform Infrared (FTIR) spectroscopic 
studies. 
 
Physical Compatibility Study 78 
               The physical compatibility studies were conducted to provide valuable 
information to the formulator in selecting the appropriate excipients for the formulation. It 
was done by mixing the drugs and the excipients and kept at room temperature and at 40⁰ 
C and 75% RH. Any change in color of the physical mixture was observed visually. 
 
Chemical Compatibility study by FTIR 55, 79 
Infrared spectroscopy can be used to identify a compound and also to investigate 
the composition of a mixture. Pure drugs, polymers, excipients, drug excipient mixture 
and the optimized formulation were subjected to FTIR studies to investigate the Drug- 
excipient interactions. The IR spectra of the test samples were obtained by Pressed Pellet 
Technique using Potassium bromide. 
 
PREPARATION OF BUFFER SOLUTIONS 
      
Preparation of 0.1 N Hydrochloric Acid (1.2 pH) 73 
8.5 mL of the hydrochloric acid was taken and dissolved in water and made upto 
1000 mL to get 0.1 N hydrochloric acid. 
 
Materials and Methods  
 
Department of Pharmaceutics, Madras Medical College  Page 63 
 
Preparation of 0.02 M potassium dihydrogen phosphate 73 
            27.218 g of potassium dihydrogen phosphate was dissolved in distilled water and 
the volume was made upto 1000 mL using distilled water. 
Preparation of 0.02 M Sodium Hydroxide 73 
      8 g of sodium hydroxide was dissolved in distilled water and made upto 1000 mL 
with distilled water. 
Preparation of 6.8 pH phosphate buffer solution 73 
           50 mL of 0.02 M Potassium dihydrogen phosphate was taken in a 200 mL 
volumetric flask. 22.4 mL of 0.02 M sodium hydroxide solution was added and mixed 
well then the volume was made upto 200 mL using distilled water. 
 
CALIBRATION CURVE 
For Metformin hydrochloride 80 
           100 mg of drug was weighed and transferred to a 100 mL standard flask and made 
upto volume using 0.1 N HCl. 10 mL of the stock solution was pipetted out in a separate 
100 mL standard flask and the volume was made up using 0.1 N HCl.  From the resulting 
solution 2, 4, 6, 8 and 10 mL were pipetted out into separate 100 mL standard flasks and 
made upto volume using 0.1 N HCl to represent 2, 4, 6, 8 and 10 µg/mL of the drug. The 
absorbance of the solutions was measured at 233 nm taking 0.1 N HCl as blank using UV- 
Visible spectrophotometer. The same procedure was repeated using 6.8 pH phosphate 
buffer solution as solvent. The calibration curve was then plotted taking concentration 
(µg/mL) along X-axis and absorbance along Y- axis. 
 
For Losartan potassium 81 
           100 mg of drug was weighed and transferred to a 100 mL standard flask and made 
upto volume using 0.1 N HCl. 10 mL of the stock solution was pipetted out in a separate 
100 mL standard flask and the volume was made up using 0.1 N HCl.  From the resulting 
solution 2, 4, 6, 8 and 10 mL were pipetted out into separate 100 mL standard flasks and 
made upto volume using 0.1 N HCl to represent 2, 4, 6, 8 and 10 µg/mL of the drug. The 
absorbance of the solutions was measured at 205 nm taking 0.1 N HCl as blank using UV- 
Visible spectrophotometer. The calibration curve was then plotted taking concentration 
(µg/mL) along X-axis and absorbance along Y- axis. 
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PRECOMPRESSION STUDIES OF DRUG AND BLEND 
FLOW PROPERTY MEASUREMENTS 77  
            The flow properties of powders are critical for an efficient tabletting operation. 
A good flow of the powder or granulation to be compressed is necessary to assure efficient 
mixing and acceptable weight uniformity for the compressed tablets. The flow property 
measurements include Bulk Density, Tapped Density, Compressibility index, Hausner’s 
ratio and Angle of Repose. The flow property measurements of drug and blends were 
determined to select the type of granulation technique to be carried out for the formulation. 
 
A. BULK DENSITY (ρb) 81 
           It is the ratio of total mass of powder to the bulk volume of powder. It was 
measured by pouring the weighed powder into a measuring cylinder. This initial volume 
was called the bulk volume. From this the bulk density was calculated according to the 
formula mentioned below. It is expressed in g/mL and is given by 
ρb = M/ Vb 
Where, M and Vb are mass of powder and bulk volume of the powder respectively. 
 
B. TAPPED DENSITY(ρt) 81 
            It is the ratio of weight of the powder to the tapped volume of powder. The 
powder was introduced into a measuring cylinder with the aid of funnel and tapped for 500 
times on a wooden surface at 2 sec interval and the volume attained was the tapped 
volume. It is expressed in g/mL and is given by 
ρt = M / Vt 
Where, M and Vt are mass of powder and tapped volume of the powder respectively. 
 
C.  ANGLE OF REPOSE (θ) 81 
           The flow properties were characterized in terms of Angle of repose, Carr’s index 
and Hausner’s ratio. For determination of Angle of Repose (θ), the drug and the blends 
were poured through the walls of a funnel, which was fixed at a position such that its 
lower tip was at a height of exactly 2.0 cm above a hard surface. The drug or the blends 
were poured till the time when upper tip of the pile surface touched the lower tip of the 
funnel. Angle of repose was calculated using following equation. 
θ = tan-1(h/r) 
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Where, h = height of pile in cm; r = radius of pile in cm 
 
D. CARR’S INDEX (OR) % COMPRESSIBILITY 81 
                          
           It indicates powder flow properties. It is measured for determining the relative 
importance of interparticulate interactions. It is expressed in percentage and is given by 
CI = ρt –ρb   X 100 
 ρt 
Where, ρt and ρb are tapped density and bulk density respectively. 
 
E. HAUSNER’S RATIO 81 
           Hausner’s ratio is an indirect index of ease of powder flow. It is calculated by the 
following formula. 
HR = ρt / ρb 
Where, ρt and ρb are tapped density and bulk density respectively. 
  
 
Table 3: Values of Angle of Repose, Compressibility Index and Hausner’s Ratio 82 
Flow property Angle of Repose (θ) Compressibility Index (%) Hausner’s Ratio 
Excellent 25-30 <10 1.00-1.11 
Good 31-35 11-15 1.12-1.18 
Fair 36-40 16-20 1.19-1.25 
Passable 41-45 21-25 1.26-1.34 
Poor 46-55 26-31 1.35-1.45 
Very poor 56-65 32-37 1.46-1.59 
Very Very poor >65 >38 >1.60 
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7. FORMULATION DEVELOPMENT 
Formulation of Immediate release granules of Losartan Potassium  
The immediate release granules of Losartan potassium (L1 and L2) were 
prepared by wet granulation technique.49 Sodium Starch Glycolate (SSG) was used as a 
super disintegrant in (2% and 4% concentrations) to improve dissolution of the drug. The 
granules were compressed by 27 station tablet compression machine using 11/32 inch 
(8.73mm) concave punches. 
 
Table 4: Composition of immediate release granules 
S.NO INGREDIENTS L1 (mg) L2 (mg) 
01. Losartan potassium 50 50 
02. Lactose 86.6 82.0 
03. Starch 69.0 69.0 
04. PVP K-30 4.6 4.6 
05. Isopropyl alcohol q.s q.s 
06. Sodium starch glycolate 4.6 9.2 
07. Magnesium stearate 4.6 4.6 
08. Tartrazine yellow 1.0 1.0 
09. Starch 10 10 
Total weight 230.0 230.0 
 
The immediate release tablet of Losartan potassium was formulated and 
optimized. The optimized formulation was used for the final bilayer tablets. 
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Flowchart for formulation of Losartan potassium immediate release (IR) tablets  
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Formulation of Sustained Release Granules  of Metformin Hydrochloride  
                    The sustained release granules were prepared by wet granulation technique. 32 
Different polymers such as HPMC K4M, HPMC K100M and ethyl cellulose are used in 
different ratios. The tablets were compressed by 27 station tablet compression machine 
using 19 x 9 mm caplet shaped punches.  
Table 5: Composition of sustained release Metformin hydrochloride tablets 
S.NO INGREDIENTS F1(mg) F2(mg) F3(mg) F4(mg) F5(mg) 
01. Metformin hydrochloride 500 500 500 500 500 
02. Ethyl cellulose 25 25 25 25 25 
03. Acetone q.s q.s q.s q.s q.s 
04. HPMC K4M 200 - 50 100 100 
05. HPMC K100M - 200 100 50 100 
06. Microcrystalline cellulose pH102 62.5 62.5 112.5 112.5 62.5 
07. PVP K-30 42.5 42.5 42.5 42.5 42.5 
08. Isopropyl alcohol q.s q.s q.s q.s q.s 
09. Magnesium stearate 10 10 10 10 10 
10. Talc 10 10 10 10 10 
Total weight 850 850 850 850 850 
 
                 The optimized batch of sustained release Metformin hydrochloride tablets was 
then compressed with the optimized batch of immediate release tablets to get bilayer 
tablets. 
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Flowchart for formulation of Metformin Hydrochloride Sustained Release Tablets 
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Flowchart for bilayer tablets of Losartan potassium and Metformin hydrochloride   
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POST COMPRESSION STUDIES 
1. PHYSICAL PARAMETERS 
A. General appearance 
    The general appearance of the tablets from each formulation batch was 
observed. The general appearance parameters are shape, colour, presence or absence of 
odour and taste. They were evaluated visually. 
 
B. Uniformity of Weight 73 
                  Twenty tablets were selected at random and weighed individually. The average 
weight was also calculated. The average weight is determined. The individual weight was 
compared with the average weight. 
Table 6: Uniformity of weight 
S.No Average weight of tablet % Deviation 
1 80 mg or less 10 
2 More than 80 mg but less than 250 mg 7.5 
3 250 mg or more 5 
 
C. Thickness and diameter 73 
                The thickness and diameter was measured to determine the uniformity of size 
and shape. Thickness and diameter of five tablets was measured using vernier caliper. 
 
D. Hardness 73 
                Hardness is defined as the force required for breaking a tablet at diametric 
compression test and it is termed as tablet crushing strength. Hardness of five tablets was 
determined using Monsanto hardness tester. It is expressed in Kg/cm2. 
 
E. Friability 73 
                Friability of the prepared formulations was determined by using Roche 
friabilator. Pre-weighed sample of tablets was placed in the friability tester, which was 
then operated for 100 revolutions, tablets were dedusted and reweighed. The friability of 
the tablets was calculated using the formula mentioned below. 
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% Friability =   Initial weight of the tablets – Final weight of the tablets X 100  
Initial weight of the tablets 
 
 
2. DRUG CONTENT 
I. FOR IR TABLETS CONTAINING LOSARTAN POTASSIUM 73 
Twenty tablets were selected randomly and ground. The powder equivalent to 50 
mg of Losartan potassium was weighed, mixed with 5 mL of methanol and made upto 100 
mL with 0.1 N HCl. The solution was filtered and 2 mL of the filtrate was diluted to 100 
mL with 0.1 N HCl. The absorbance of the resulting solution was measured at 205 nm 
taking 0.1 N HCl as blank using UV-visible Spectrophotometer.  
FOR SR TABLETS CONTAINING METFORMIN HYDROCHLORIDE 73 
             Twenty tablets were selected randomly and ground. The powder equivalent to 85 
mg of Metformin hydrochloride was weighed, mixed with 5 mL of methanol and made 
upto 100 mL with 6.8 pH phosphate buffer solution. The solution was filtered and 2mL of 
the filtrate was diluted to 100 mL of 6.8 pH phosphate buffer solution.  The absorbance of 
the resulting solution was measured at 233 nm taking 6.8 pH phosphate buffer solution as 
blank using UV-visible Spectrophotometer.  
II. BILAYER TABLETS OF LOSARTAN POTASSIUM AND METFORMIN 
HYDROCHLORIDE (SIMULATANEOUS EQUATION METHOD) 83 
Simultaneous estimation of Losartan potassium and Metformin hydrochloride was 
carried out using UV-Visible Spectrophotometer. 
PROCEDURE 
The following equations were used to determine the contents. 
Cx = A2ay1 – A1ay2 
                                        Ax2ay1-ax1ay2 
Cy = A1ax2 – A2ax1 
                                        Ax2ay1-ax1ay2 
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Where   ax1 and ax2 = The absorptivity of drug X at λ1 and λ2 respectively. 
             ay1 and ay2 =  The  absorptivity of drug Y at λ1 and λ2 respectively. 
             A1 and A2 = The absorbance of sample at λ1 and λ2 respectively. 
               The ratios                 A1/ A2       and      ay1/ ay2 
                                    ax1 / ax2                          A1/ A2      should lie outside the range 
of 0.1 – 2.0 for the precise determination of X and Y drugs. This criteria is satisfied only 
when the λmax of the two components is reasonably dissimilar and the components should 
not interact chemically.   
Preparation of standard stock solution of Losartan potassium 
Losartan potassium equivalent to 50 mg was accurately weighed. 50 mL of 0.1 N 
HCl was added and sonicated for 10 min. The volume was made upto 100 mL with 0.1 N 
HCl. 2 mL of the solution was diluted to 100 mL with 0.1 N HCl. 
Preparation of standard stock solution of Metformin hydrochloride 
             Metformin hydrochloride equivalent to 50 mg was accurately weighed. 50 mL of 
0.1 N HCl was added and sonicated for 10 min. The volume was made upto 100 mL with 
0.1 N HCl. 2 mL of the solution was diluted to 100 mL with 0.1 N HCl. 
Preparation of sample solution 
             Twenty tablets were accurately weighed and the average weight was calculated. 
The tablets were then ground to a fine powder. Powder equivalent to 100 mg of Metformin 
hydrochloride was weighed and transferred to a 100 mL standard flask. The powder was 
then dissolved in 0.1 N HCl and sonicated. The volume was made upto 100 mL with 0.1 N 
HCl. 2 mL of the solution was diluted to 100 mL with 0.1 N HCl. The absorbance of the 
resulting solution was measured at 205 nm and 233 nm respectively. The amount of both 
the drugs was determined. 
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3. In vitro disintegration studies for IR tablets 73 
The disintegration time was determined using disintegration test apparatus. The 
tablets were placed in each of the six tubes of the basket. The assembly was suspended in 
water maintained at a temperature of 37⁰C ± 2⁰C and the apparatus was switched on. The 
time taken to disintegrate the tablets completely was noted. 
4. In vitro dissolution studies 
For IR tablets 
        The release of Losartan was determined using USP Type II (paddle) dissolution 
apparatus under sink condition.  900 mL of 0.1 N HCl was used as dissolution medium at 
a temperature of 37⁰C ± 0.5⁰C.  The paddle was stirred at a speed of 100 rpm. The release 
studies were carried out for 30 min. The absorbance of the solution was measured at 205 
nm taking 0.1 N HCl as blank using UV- Visible spectrophotometer. 
For SR tablets 
   The release of Metformin hydrochloride was determined using USP Type II 
(paddle) dissolution apparatus under sink condition.  900 mL of 0.1 N HCl was used as 
dissolution medium for first two hours followed by 900 mL of pH 6.8 phosphate buffer 
solution for next eight hours maintained at a temperature of 37⁰C ± 0.5⁰C.  The paddle 
was stirred at a speed of 100 rpm. The release studies were carried out for ten hours. The 
absorbance of the solution was measured at 233 nm taking respective buffer solutions as 
blank using UV- Visible spectrophotometer. 
For Bilayer tablets 
           The release of bilayer tablets was determined using USP Type II (paddle) 
dissolution apparatus under sink condition.  900 mL of 0.1 N HCl was used as dissolution 
medium for first two hours followed by 900 mL of pH 6.8 phosphate buffer solution for 
next eight hours maintained at a temperature of 37⁰C ± 0.5⁰C.  The paddle was stirred at a 
speed of 100 rpm. The release studies were carried out for ten hours. The absorbance of 
the solution as measured at 205 nm and 233 nm taking respective buffer solutions as blank 
using UV- Visible spectrophotometer.  
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5.  In vitro release kinetics 84 
 To study the in vitro release kinetics of the optimized bilayer tablets, data obtained 
from in vitro dissolution study were plotted in various kinetic models.   
 
i) Zero order equation  
             The zero order release kinetics can be obtained by plotting cumulative % drug 
released Vs Time (hours). It is ideal for the formulation to have release profile of zero 
order to achieve pharmacological prolonged action. 
C = K0t 
Where, K0 = Zero order constant in Conc./ time 
              t = Time in hours 
 
ii) First order equation  
            A graph was plotted with log % cumulative drug remaining Vs Time in hours. 
Log C = logC0 – Kt/2.303 
C0 = Initial drug concentration 
K = First order constant 
  t = Time in hours.    
 
iii) Higuchi kinetics 
          A graph was plotted with % cumulative drug released Vs Square root of time. 
Q = Kt1/2 
K = Constant reflecting design variable system (Differential rate constant) 
t = Time in hours. 
 The drug release rate is inversely proportional to the square root of time. 
 
iv) Hixson and Crowell erosion equation 
            To evaluate the drug release with changes in the surface area and the diameter of 
particles, the data were plotted using the Hixson and Crowell erosion equation. A graph 
was plotted with cube root of % drug remaining Vs Time in hours. 
 
Q01/3 – Qt1/3 = KHC X t 
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Qt = Amount of drug released at time t 
Q0 = Initial amount of drug 
KHC = Rate constant for Hixson Crowell equation 
 
v) Korsmeyer – Peppas equation 
       To evaluate the mechanism of drug release, it was further plotted in Peppas equation 
as log cumulative % of drug released Vs log time. 
Mt/Mα = Ktn 
 Where Mt/Mα = Fraction of drug released at time t 
                  t = Release time  
                  K = Kinetics constant (Incorporating structural and geometric characteristics of    
                    the formulation)  
                   n = Diffusional exponent indicative of the mechanism of drug release. 
 
Table 7: Diffusion exponent and solute release mechanism for cylindrical shape 
 
Diffusion exponent (n) Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45  < n < 0.89 Anomalous (non-Fickian) diffusion 
0.89 Case-II transport 
n > 0.89 Super case-II transport 
 
vi) Stability Study 85 
        Stability study of optimized bilayer tablets was carried out according to ICH 
guidelines. All the tablets were packed in blister and kept in a humidity chamber at          
40⁰ ± 2⁰C and 75% ± 5% RH for 3 months. Samples were withdrawn at monthly intervals 
and analyzed for uniformity of weight, thickness, hardness, friability, drug content and in 
vitro drug release. 
   
  
 
 
 
 
 
 
 
     
        Results & Discussion 
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8. RESULTS AND DISCUSSION 
           The present investigation was to formulate bilayer tablets for immediate release 
of Losartan potassium and sustained release of Metformin hydrochloride to treat 
hypertension in Type II Diabetes Mellitus. 
PREFORMULATION STUDIES 
DRUG -EXCIPIENT COMPATIBILITY STUDY 
             The drug excipient study was conducted to reveal the excipient compatibility 
with the drug. The physical compatibility of drug and excipients are given in table 8. 
Table 8: Physical compatibility study of drug and Excipients 
 
 
 
S.No  
 
 
Drug + 
Excipient 
Description and condition 
 
 
Initial 
 
Room temperature and 
40⁰C/75% RH in days 
 
10th 20th 30th 
01. LP A white to off white crystalline 
powder 
 
NC NC NC 
02. MH A white, hygroscopic, 
crystalline powder. NC NC NC 
03. LP + MH White almost crystalline 
powder NC NC NC 
04. Lactose White to off –white crystalline 
powder NC NC NC 
05. Starch White to off -white powder NC NC NC 
06. PVP K30 White or creamy white 
hygroscopic powder NC NC NC 
07. SSG White or almost white free 
flowing  very hygroscopic 
powder 
NC NC NC 
08. Tartrazine yellow Yellow coloured crystalline 
powder NC NC NC 
09. Magnesium 
stearate 
White or almost white 
crystalline powder NC NC NC 
10. HPMC K4M White or creamy white powder NC NC NC 
11. HPMC K100M White or creamy white powder NC NC NC 
12. Ethyl cellulose Free- flowing, white coloured 
powder NC NC NC 
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13. MCC pH 102 White crystalline powder NC NC NC 
14. Talc White or creamy white soft 
powder NC NC NC 
15. LP + Lactose White or crystalline powder NC NC NC 
16. LP + Starch  White or crystalline powder NC NC NC 
17. LP + PVP K 30 White or crystalline powder NC NC NC 
18. LP + SSG Free flowing white crystalline 
powder NC NC NC 
19. LP + TY Free flowing yellow colour 
powder NC NC NC 
20. LP + Magnesium 
Stearate 
White, crystalline powder NC NC NC 
21. MH +HPMC 
K4M 
White, creamy white crystalline 
powder NC NC NC 
22. MH + HPMC 
K100M 
White, creamy white crystalline 
powder NC NC NC 
23. MH + EC White, almost white crystalline 
powder NC NC NC 
24. MH +MCC pH 
102 
White, almost white crystalline 
powder NC NC NC 
25. MH+ PVP K30 White, creamy white crystalline 
powder NC NC NC 
26. MH + 
Magnesium 
Stearate 
White crystalline powder 
NC NC NC 
27. MH + Talc White or creamy white powder NC NC NC 
NC – No Change 
              The physical compatibility was performed visually. The study reveals that the 
drug and the excipients were physically compatible with each other as there was no 
change of physical parameters. The excipients which were compatible with the drug 
were selected for the formulation. 
 
 
 
 
 
 
 Department of Pharmaceutics, Madras Medical College
 
Chemical Compatibility 
 The possible interaction between the drugs and excipients used in the formulation was 
studied by FTIR spectroscopy. 
 
Table 9: IR Spectral Interpretation of Losartan Potassium
S.No Wave Number (cm
01. 3181.81
02. 2957.19
03. 1637.79
04. 1579.35
05. 1459.86
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study 
The results are given in the Figures  
Fig. 11: FTIR of Losartan potassium 
 
 
-1) Interpretation 
 C-H stretching vibrations (Aromatic)
,2869.61 C-H stretching vibrations (Alkane)
 C=C stretching vibrations
 C-C stretching vibrations
 C-H bending vibrations
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Fig
Table 10: IR Spectral Interpretation of Metformin Hydrochloride
S.No Wave Number (cm
01. 3366.93
02. 3164.04
03. 2699.93
04. 2218.76
05. 1622.06
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. 12: FTIR of Metformin Hydrochloride 
 
 
-1) Interpretation 
,3303.45 N-H stretching vibrations (1⁰
 
N-H stretching vibrations (2⁰
 C-H stretching vibrations
 C=N stretching vibrations
 N-H bending vibrations
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Fig. 13: FTIR of Losartan Potassium and Metformin Hydrochloride
 
 
Table 11: IR Spectral Interpretation of Losartan Potassium
S.No Wave Number (cm
01. 3382.69
02. 3174.69
03. 2959.94
04. 2217.03
05. 1573.83
INFERENCE 
  The FTIR 
Hydrochloride showed no shift and no disappearance of the 
suggesting that there is no interaction between the
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 and Metformin 
-1) Interpretation 
 N-H stretching vibrations
 C-H stretching vibrations (Aromatic)
 C-H stretching vibrations (Alkane
 C=N stretching vibrations
 N-H bending vibrations
 
peak of Spectra for Losartan Potassium and Metformin 
characteristic
 two drugs.  
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Fig. 14: FTIR Metformin Hydrochloride and HPMC K4M 
 
 
Table 12: IR Spectral Interpretation of Metformin Hydrochloride + HPMC K4M 
S.No Wave Number (cm-1) Interpretation 
01. 3351.82 (2⁰ amine) N-H stretching vibrations 
02. 3173.45 (1⁰ amine) N-H stretching vibrations 
03. 2216.62 C=N stretching vibrations 
04. 1627.50 N-H bending Vibrations 
 
INFERENCE 
  The FTIR peak of Spectra for Metformin Hydrochloride and HPMC K4M 
showed no shift and no disappearance of the characteristic peaks suggesting that there is 
no interaction between the drug and the excipient.  
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 Fig. 15: FTIR of Metformin hydrochloride and HPMC K100M 
 
Table 13: IR Spectral Interpretation of Metformin Hydrochloride + HPMC K100M 
S.No Wave Number (cm-1) Interpretation 
01. 3389.92, 3344.44 N-H stretching vibrations (1⁰ amine) 
02. 3187.26 N-H stretching vibrations (2⁰ amine) 
03. 2936.45 C-H stretching vibrations 
04. 2215.80 C=N stretching vibrations 
05. 1566.06 N-H bending vibrations 
 
INFERENCE 
  The FTIR peak of Spectra for Metformin Hydrochloride and HPMC 
K100M showed no shift and no disappearance of the characteristic peaks suggesting 
that there is no interaction between the drug and the excipient. 
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Fig. 16: FTIR of Metformin Hydrochloride and Ethyl Cellulose 
 
 
Table 14: IR Spectral Interpretation of Metformin Hydrochloride + Ethyl Cellulose 
S.No Wave Number (cm-1) Interpretation 
01. 3376.10 (1⁰ amine) N-H stretching vibrations 
02. 3184.19 (2⁰ amine) N-H stretching vibrations 
03.  2927.72 C-H stretching vibrations 
04 2218.76 C=N stretching vibrations 
05. 1558.43 N-H bending vibrations 
 
INFERENCE 
  The FTIR peak of Spectra for Metformin Hydrochloride and Ethylcellulose 
showed no shift and no disappearance of the characteristic peaks suggesting that there is 
no interaction between the drug and the excipient. 
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Fig. 17: FTIR of Bilayer Formulation  
 
 
Table 15: IR Spectral Interpretation of Losartan Potassium and Metformin HCl 
S.No Wave Number (cm-1) Interpretation 
01. 3382.69 N-H stretching vibrations 
02. 3174.69 C-H stretching vibrations (Aromatic) 
03. 2959.94 C-H stretching vibrations (Alkane) 
04. 2217.03 C=N stretching vibrations 
05. 1573.83 N-H bending vibrations 
 
INFERENCE 
  The FTIR peak of Spectra for final bilayer formulation showed no shift and 
no disappearance of the characteristic peaks suggesting that there is no interaction 
between the two drugs and also with the excipients in the final formulation.  
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CALIBRATION CURVE FOR LOSARTAN POTASSIUM
The calibration curve of Losa
Table 16: Data for calibration curve of Losartan potassium in 0.1N 
Concentration (µg/
 
Fig. 18: Calibration Curve of Losartan potassium in 0.1N HCl
                              It was found that the 
show linearity (R2 = 0.9998) in absorbance at concentrations 
Beer Lambert Law. 
0
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mL) Absorbance at λ205nm 
0 0.000 
2 0.1430 
4 0.2809 
6 0.4301 
8 0.5701 
10 0.7020 
 
solution of Losartan Potassium
of 2 -10 (
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CALIBRATION CURVE FOR METFORMIN HYDROCHLORIDE 
 The calibration curve of Metformin hydrochloride in 0.1N HCl and 6.8 pH 
phosphate buffer is given in Table 17, 18 and Fig 19, 20.  
Table 17: Data for calibration curve of Metformin hydrochloride in 0.1N HCl 
Concentration (µg/mL) Absorbance at λ233nm 
0 0.000 
2 0.0668 
4 0.1356 
6 0.2009 
8 0.2768 
10 0.3402 
 
 
Fig. 19: Calibration curve of Metformin hydrochloride in 0.1 N HCl 
                          
               It was found that the solution of Metformin hydrochloride in 0.1 N HCl show 
linearity (R2 = 0.9996) in absorbance at concentrations of 2 -10 (µg/mL) and obey Beer 
Lambert Law. 
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Table 18: Data for calibration curve of Metformin hydrochloride in pH 6.8 
Phosphate Buffer 
Concentration (µg/mL) Absorbance at λ233nm 
0 0.000 
2 0.1419 
4 0.2845 
6 0.4235 
8 0.5818 
10 0.7362 
 
 
 
Fig. 20: Calibration curve of Metformin hydrochloride in 6.8 pH Phosphate Buffer 
                           
                            It was found that the solution of Metformin hydrochloride in 6.8 pH 
phosphate buffer show linearity (R2 = 0.9996) in absorbance at concentrations of 2 -10 
(µg/mL) and obey Beer Lambert Law. 
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FOR IR FORMULATION 
PRECOMPRESSION STUDY 
The drug and the formulated blends were evaluated for precompression parameters. The 
results are given in Table 19. 
Table 19: Precompression study of drug and formulated blends 
Drug and 
blends 
Bulk 
Density 
g/mL* 
Tapped 
Density 
g/mL * 
Compressibility 
index (%)* 
Hausner’s 
Ratio * 
Angle of 
Repose 
(Degree)* 
LP 
0.4203 ± 
0.0095 
0.5733 ± 
0.0032 
26.69 ± 
1.6348 
1.36 ± 
0.0321 
42.47 ± 
0.0458 
L1 
0.5226 ± 
0.0099 
0.6427 ± 
0.0079 
18.69 ± 
0.5464 
1.23 ± 
0.01 
28.25 ± 
0.0252 
L2 
0.5251 ± 
0.0056 
0.6288 ± 
0.0261 
16.36 ± 
4.2933 
1.20 ± 
0.0651 
29.56 ± 
0.0208 
* Mean ± S.D (n = 3) 
  The bulk density of the IR blends ranged from 0.5226 g/mL to 0.5251 g/mL 
and the tapped density ranged from 0.6288 g/mL to 0.6427 g/mL. The compressibility 
index of the IR blends ranged from 16.36% to 18.67% and Hausner’s ratio ranged from 
1.20 to 1.23. The angle of repose of the IR blends ranged from 28.25 to 29.56. The 
formulated blends show a fair compressibility index and poor flow.82 So, wet 
granulation technique was used for preparing IR granules of Losartan potassium. 
                   The IR granules were evaluated for bulk density, tapped density, 
compressibility index, Hausner’s ratio and Angle of Repose. The results are given in 
Table 20.   
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Table 20: Precompression study of immediate release granules 
Formulation 
Bulk 
Density 
g/mL * 
Tapped 
Density 
g/mL *
 
Compressibility 
index (%)* 
Hausner’s 
Ratio * 
Angle of 
Repose 
(Degree)* 
L1 
0.5522 ± 
0.0041 
0.6518 ± 
0.0056 
15.28  ±  
0.3510 
1.18 ± 
0.0058 
21.50 ± 
0.0529 
L2 
0.5481 ± 
0.0103 
0.6503 ± 
0.0065 
15.31 ± 
0.8995 
1.19 ± 
0.0173 
21.48 ± 
0.0265 
 * Mean ± S.D (n = 3) 
         The bulk density of the IR granules ranged from 0.5481 g/mL to 0.5522 g/mL and 
the tapped density of ranged from 0.6503 g/mL to 0.6518 g/mL. The compressibility 
index of the IR granules ranged from 15.28% to 15.31% and Hausner’s ratio ranged 
from 1.18 to 1.19. The angle of repose of the IR granules ranged from 21.48 to 21.50. 
The granules showed good flow property.82 
 
FORMULATION DEVELOPMENT 
Preparation of IR tablets of Losartan potassium 
             Wet granulation technique was employed for the formulation of IR granules 
of Losartan potassium. 
   The prepared tablets were easy to prepare and of uniform shape and size.  
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POST COMPRESSION STUDY FOR TABLETS 
UNIFORMITY OF WEIGHT 
              The uniformity of weight of the formulated tablets is given in Table 21. 
Table 21: Uniformity of weight of the formulated tablets 
Formulation Uniformity of weight (mg) * 
L1 230.50 ± 0.0004 
L2 230.50 ± 0.0005 
* Mean ± S.D (n=20) 
       The formulated tablets complies with the test for uniformity of weight.73 
TABLET THICKNESS AND DIAMETER 
            The thickness and diameter of the formulated tablets is given in table 22.  
Table 22: Thickness and Diameter of formulated tablets  
Formulation Thickness (mm) * Diameter (mm) * 
L1 3.290±0.014 8.769 ± 0.0088 
L2 3.302±0.015 8.770 ± 0.0089 
* Mean ± S.D (n=5) 
The formulated tablets had uniform thickness and diameter. 
HARDNESS 
The hardness of the formulated tablets is given in table 23. 
Table 23: Hardness of formulated tablets 
Formulation Hardness (Kg/cm2) * 
L1 3.10±0.22 
L2 3.20±0.27 
* Mean ± S.D (n=5) 
All the formulated tablets showed sufficient mechanical strength to resist the 
transportation.79 
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   FRIABILITY  
The friability of the form
Table 24
   The percentage friability of all the formulations were
DRUG CONTENT 
The drug content of the IR tablets is give
Table 25
The drug content of the IR tablets was 
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ulated tablets is given in table 24. 
: Friability of formulated tablets 
Formulation % Friability *  
L1 0.086 ± 0.0040 
L2 0.173 ± 0.0130 
* Mean ± S.D (n=3) 
 within the acceptable limits
n in the table 25 and fig.21. 
: Drug content of formulated IR tablets
Formulation % Drug Content * 
L1 97.760 ± 0.260 
L2 98.219 ± 0.804  
* Mean ± S.D (n=3)         
         
Fig. 21: Drug content of IR tablets    
           
within Pharmacopoeial limits.73
98
L1 L2Formulation
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DISINTEGRATION TIME
The disintegration time of the I
Table 26
Formulation
L1
L2
 
Fig. 22: Disintegration time of IR tablets
The disintegration time of the IR
disintegration time of the IR tablets containing 4% sodium starch glycolate was found 
to have faster disintegration time for IR tablets.
IN VITRO DISSOLUTION STUDY
                     The in vitro
potassium is given in table 27
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R tablets is given in the table 26 and fig. 22
: Disintegration time of IR tablets 
 Disintegration time (minutes) * 
 12’45’’ ± 0.4147 
 4’52’’ ± 0.4493  
* Mean ± S.D (n=6) 
 
 
 tablets ranged from 4’52
19 
 
 dissolution of immediate release formulations of 
 and fig. 23. 
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Table 27: In vitro Dissolution study of Immediate release formulation of Losartan 
potassium  
                                                                                  
 
 
 
 
Fig. 23: In vitro Dissolution study of IR tablets of Losartan potassium
 
  The in vitro 
SSG was found to be optimum for immediate release of Losartan potassium. The
concentration of SSG was found to be releasing the drug slowly when compared to 4
SSG. The formulation containing 4
of 30 min. Therefore formulation L2 was optimized and selected for final bilayer 
tablets.30 
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* Mean ± S.D (n=3) 
dissolution study of IR tablets showed that 4% concentration of 
 % of SSG showed drug release of
10 20 30 40 50
Time (Minutes)
 
 
Cumulative % drug release *  
L1 L2 
0 0 ± 0.0000 0 ± 0.0000 
10 91.34 ± 0.4812 89.35 ± 0.36 
20 93.64 ± 0.2107 95.38 ± 0.40 
30 95.80 ± 0.5568 98.45 ±  0.15 
40 96.92 ± 0.0900 
 
50 98.03 ± 0.5300 
 
60 99.04 ± 0.1400 
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SR TABLETS 
PRECOMPRESSION STUDY  
The drug and the formulated blends of SR are evaluated for precompression parameters. 
The results are given in the table 28.   
Table 28: Precompression study of drug and formulated blends 
Drug and 
formulation 
Blend 
Bulk 
density 
g/mL * 
Tapped 
density 
g/mL * 
Compressibility 
Index (%)*  
Hausner’s 
Ratio * 
Angle of 
Repose  
(Degree)* 
MH 
0.5613 ± 
0.0029 
0.6763 ± 
0.0086 
17.00 ± 
0.8113 
1.21 ± 
0.0153 
42.37 ± 
0.0153 
F1 
0.4304 ± 
0.0069 
0.5462 ± 
0.0094 
21.19 ±  
0.6920 
1.27 ± 
0.01 
32.53 ± 
0.0153 
F2 
0.4309 ± 
0.0070 
0.5438 ± 
0.0097 
20.76 ± 
0.0656 
1.26 ± 
0.0265 
32.08 ± 
0.0300 
F3 
0.4276 ± 
0.0044 
0.5425 ± 
0.017 
21.18 ± 
0.1900 
1.27 ± 
0.0265 
32.01 ± 
0.0520 
F4 
0.4272 ± 
.0.0036 
0.5397 ± 
0.0058 
20.84 ± 
0.0702 
1.26 ± 
0.0208 
32.55 ± 
0.0252 
F5 
0.4273 ± 
0.0049 
0.5462 ± 
0.014 
21.76 ± 
0.0600 
1.28 ± 
0.0473 
31.33 ± 
0.0252 
* Mean ± S.D (n=3) 
                         The bulk density of the SR blends ranged from 0.4272 g/mL to 0.4309 
g/mL and the tapped density ranged from 0.5397 g/mL to 0.5462 g/mL. The 
compressibility index of the SR blend ranged from 20.53 to 21.76 and Hausner’s ratio 
ranged from 1.26 to 1.28. The angle of repose of the SR blend ranged from 31.33 to 
32.55. The formulated blends showed poor flow property. Hence, wet granulation 
technique was used for preparation SR granules of Metformin hydrochloride. 
                         The SR granules were evaluated for bulk density, tapped density, 
compressibility index, Hausner’s ratio and Angle of Repose. The results are given in 
Table 29. 
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Table 29: Precompression study of sustained release granules 
 
Formulation 
Bulk 
density 
g/mL * 
Tapped 
density 
g/mL * 
Compressibility 
Index (%)* 
Hausner’s 
Ratio * 
Angle of 
Repose   
(Degree) * 
F1 
0.4274 ± 
0.0013 
0.4773 ± 
0.0123 
10.44 ±  
0.2476 
1.12 ± 
0.0252 
25.49 ± 
0.0200 
F2 
0.4225 ± 
0.0015 
0.4753 ± 
0.0115 
11.11 ± 
0.0600 
1.12 ± 
0.0252 
25.01 ± 
0.0208 
F3 
0.4212 ± 
0.0053 
0.4793 ± 
0.0131 
12.12 ± 
0.1200 
1.14 ± 
0.0416 
24.30 ± 
0.0361 
F4 
0.4252 ± 
0.0040 
0.4714 ± 
0.0085 
9.78 ± 
0.0200 
1.11 ± 
0.0153 
24.15 ± 
0.0200 
F5 
0.4176 ± 
0.0056 
0.4792 ± 
0.0062 
12.85 ±  
0.0500 
1.15 ± 
0.0208 
23.20 ± 
0.0153 
                   * Mean ± S.D (n=3) 
    The bulk density of the SR granules ranged from 0.4176 g/mL to 0.4274 g/mL and 
the tapped density ranged from 0.4714 g/mL to 0.4793 g/mL. The compressibility index 
of the SR granules ranged from 9.80 to 12.85% and Hausner’s ratio ranged from 1.11 to 
1.15. The Angle of Repose of the SR granules ranged from 23.20 to 25.49. The 
formulated blend showed good flow property.82 
FORMULATION DEVELOPMENT 
                   Wet granulation technique was employed for the preparation of SR granules 
of Metformin hydrochloride. 
                   Five batches of SR granules were prepared by using hydrophilic polymers 
HPMC K4M and HPMC K100M in varying proportions. The formulations were 
compressed on a 27 station tablet compression machine using 19 x 9 mm caplet shaped 
punches. 
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POST COMPRESSION STUDY 
UNIFORMITY OF WEIGHT 
                   The uniformity of weight for the formulated tablets is given in table 30. 
 
Table 30: Uniformity of Weight 
 
Formulation Uniformity of weight (mg) * 
F1 851.55 ± 0.0016 
F2 851.10 ± 0.0018 
F3 851.60 ± 0.0020 
F4 850.65 ± 0.0015 
F5 850.95 ± 0.0015 
* Mean ± S.D (n=20) 
The formulated tablet complies with the uniformity of weight.73 
 
TABLET THICKNESS  
The thickness of the formulated tablets is given in table 30. 
 
Table 31: Thickness of formulated tablets  
Formulation Thickness (mm) * 
F1 5.35 ± 0.0130 
F2 5.34 ± 0.0150 
F3 5.35 ± 0.0084 
F4 5.33 ± 0.0084 
F5 5.34 ± 0.0084 
* Mean ± S.D (n=5) 
The formulated tablets were uniform in thickness. 
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HARDNESS 
The hardness of the formulated tablets is given in table 32. 
Table 32: Hardness of formulated tablets  
Formulation Hardness Kg/cm2 * 
F1 4.0 ± 0.0447 
F2 4.0 ± 0.0548 
F3 4.0 ± 0.0447 
F4 4.0 ± 0.0447 
F5 4.0 ± 0.0548 
* Mean ± S.D (n=5) 
All the formulated tablets showed sufficient mechanical strength to resist the 
transportation.79 
 
FRIABILITY 
The friability of the formulated tablets is given in table 33.  
 
Table 33: Friability of formulated tablets  
Formulation Friability (%) * 
F1 0.017 ± 0.0020 
F2 0.023 ± 0.0020 
F3 0.018 ± 0.0020 
F4 0.020 ± 0.0050 
F5 0.035 ± 0.0050 
* Mean ± S.D (n=3) 
 
 The percentage friability of all formulations were within the acceptable limits.73 
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DRUG CONTENT 
The drug content of the SR tablets is given in the table 34
Table 34: Drug content
 
 
 
The drug content of the S
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 of formulated SR tablets
Formulation % Drug content  * 
F1 99.79± 0.0900 
F2 98.86 ± 0.0800 
F3 99.40 ± 0.0100 
F4 99.03 ± 0.0902 
F5 99.16 ± 0.2600 
* Mean ± S.D (n=3) 
Fig. 24: Drug content of SR tablets             
R tablets were within the Pharmacopoeial limits
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IN VITRO DISSOLUTION STUDY 
 The in vitro dissolution study of the formulated SR tablets is given in table 35 and 
fig.25. 
Table 35: In vitro dissolution study of SR tablets 
TIME 
(MIN) 
Cum. % drug Release 
F1 * F2 * F3 * F4 * F5 * 
0 
0  ±  
0.0000 
0  ± 
0.0000 
0  ± 
0.0000 
0  ± 
0.0000 
0  ± 
0.0000 
30 
13.15 ± 
0.0500 
5.95  ± 
0.1500 
15.78  ± 
0.0200 
16.99  ± 
0.0600 
15.15  ± 
0.0500 
60 
18.77  ± 
0.1300 
9.80  ± 
0.1300 
19.80  ± 
0.0800 
26.49  ± 
0.1400 
25.10  ± 
0.0500 
90 
23.07  ± 
0.0900 
12.38  ± 
0.1600 
24.01  ± 
0.7200 
29.35  ± 
0.1500 
31.58  ± 
0.3400 
120 
32.31  ± 
0.2900 
17.20  ± 
0.1800 
27.95  ± 
0.1500 
33.46  ± 
0.4500 
36.37  ± 
0.2100 
180 
37.53  ± 
0.5100 
27.15  ± 
0.3000 
36.46  ± 
0.1700 
36.96  ± 
0.1700 
45.29  ± 
0.2100 
240 
56.3  ± 
0.2600 
39.97  ± 
0.0700 
47.74  ± 
0.1600 
50.25  ± 
0.4500 
54.55  ± 
0.3500 
300 
72.38  ± 
0.2200 
51.02  ± 
0.0800 
55.93  ± 
0.1700 
65.99  ± 
0.1100 
60.12  ± 
0.0800 
360 
85.67  ± 
0.2300 
61.82  ± 
0.2200 
61.75  ± 
0.0800 
82.10  ± 
0.5000 
66.20  ± 
0.1500 
420 
97.38  ± 
0.4200 
73.98  ± 
0.0400 
71.06  ± 
0.4800 
85.62  ± 
0.1400 
73.60  ± 
0.5000 
480 
 
82.85  ± 
0.2500 
79.49  ± 
0.3900 
89.82  ± 
0.3200 
82.80  ± 
0.2700 
600 
 
86.87  ± 
0.0600 
85.32 ± 
0.1400 
97.17 ± 
0.1300 
92.25 ±  
0.0500 
 * Mean ± S.D (n=3) 
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Fig. 25: In vitro dissolution study of SR tablets 
 
 The results of in vitro dissolution study of SR tablets showed that the 
formulation F1 containing Ethyl cellulose and HPMC K4M showed complete release in 
7 hours. The formulation F2 containing Ethyl cellulose and HPMC K100M retarded the 
release as the concentration of Hydrophilic polymer was high. In formulations F3 and 
F4 containing ethyl cellulose, HPMC K4M and HPMC K100M in different proportions 
the release was retarded but did not meet the IP specifications. In formulation F5 
containing Ethyl cellulose, HPMC K4M and HPMC K100M in 1:1 ratio, the release 
was sustained and it met the specifications as per IP.73 Based on the release, formulation 
F5 was optimized for the final preparation of bilayer tablets.  
 
FORMULATION DEVELOPMENT 
 
PREPARATION OF BILAYER TABLETS 
1. Optimized immediate layer of Losartan potassium was prepared by wet granulation 
method. 
2. Optimized sustained release layer of Metformin hydrochloride was prepared by wet 
granulation method 
        The granules were compressed on 27 station bilayer tablet compression 
machine using 19 x 9 mm caplet shaped punches.  
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POST COMPRESSION STUDY OF BILAYER TABLETS 
  The compressed bilayer tablets were evaluated for following parameters 
and the values are given in table 36. 
 
Table 36: Post Compression Study of Bilayer Tablets 
Parameter Result 
Uniformity of weight (g) * 1.0814±0.0046 
Thickness (mm) ** 6.60±0.0055 
Hardness (kg/cm2) ** 7.0 ± 0.0447 
Friability (%) *** 0.14 ± 0.0200 
Drug content (Simultaneous Estimation Method) *** 
i)  Losartan potassium (%) 
ii) Metformin hydrochloride (%) 
 
97.36 ± 0.1400  
95.29 ± 0.2700 
* Mean ± S.D (n=20), ** Mean ± S.D (n=5), *** Mean ± S.D (n=3) 
 
IN VITRO DISSOLUTION STUDY 
 The in vitro dissolution of drugs in bilayer tablets is given in table 37, 38 and fig.   
26 and 27. 
 
 
Table 37:  In vitro dissolution study of Losartan potassium in bilayer tablets 
 
Time (Min) Cum. % Drug Release * 
0 0.0 ± 0.0000 
10 87.61 ± 0.2200 
20 93.76 ± 0.3100 
30 98.74 ± 0.1800 
*Mean ± S.D (n=3) 
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Fig. 26: In vitro Dissolution study of Losartan potassium in bilayer tablets 
 
 Table 38: In vitro dissolution study of Metformin hydrochloride in bilayer tablets 
Time (Min) 
 Cum.% Drug Release*  
0 0.0 ± 0.0000 
30 12.02 ± 0.0300 
60 25.18 ± 0.1200 
90 30.02 ± 0.0800 
120 33.96 ± 0.1600 
180 45.05 ± 0.0500 
240 53.62 ± 0.3900 
300 59.07 ± 0.7600 
360 65.77 ± 0.6500 
420 72.35 ± 0.3900 
480 81.96 ± 0.1000 
540 85.44 ± 0.5800 
600 91.38 ± 0.1200 
*Mean ± S.D (n=3) 
 
 
Fig. 27: In vitro Dissolution study of Metformin hydrochloride in bilayer tablets 
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  The bilayer tablets showed release of 98.74% of Losartan Potassium in 30 
min. the tablets released 25.18% of Metformin Hydrochloride in 1 hour, 45.05% of 
Metformin hydrochloride in 3 hours and 91.38% of Metformin hydrochloride at the end 
of 10 hours respectively. The drug release of the bilayer formulation was within the 
Pharmacopoeial limits.73  
 
IN VITRO RELEASE KINETICS 
  The values obtained from in vitro dissolution of Metformin hydrochloride 
from bilayer tablets were fitted in various kinetics models. The results are given in table 
39 and fig. 28, 29, 30, 31, 32. 
 
Table 39: In vitro release kinetics of bilayer tablets 
Time 
(Hours) 
% Cum 
Drug 
Release 
% Cum 
Drug 
Remaining 
Log % Cum 
Drug 
Remaining 
Square 
root of 
time 
Log 
time 
Log % 
cum drug 
release 
Cube root 
of  % drug 
remaining 
0 0 100 2 0 ∞ ∞ 4.6416 
0.5 12.02 87.98 1.94438 0.7071 -0.3010 1.0799 4.4476 
1 25.18 74.82 1.87402 1 0 1.4011 4.2138 
1.5 30.02 69.98 1.84497 1.2247 0.1761 1.4774 4.1209 
2 33.96 66.04 1.81981 1.4142 0.3010 1.5310 4.0421 
3 45.05 54.95 1.73997 1.7321 0.4771 1.6537 3.8018 
4 53.62 46.38 1.66633 2 0.6021 1.7293 3.5929 
5 59.07 40.93 1.61204 2.2361 0.6990 1.7714 3.4463 
6 65.77 34.23 1.53441 2.4495 0.7782 1.8180 3.2469 
7 72.35 27.65 1.44169 2.6458 0.8451 1.8594 3.0239 
8 81.96 18.04 1.25624 2.8284 0.9031 1.9136 2.6227 
9 85.44 14.56 1.16316 3 0.9542 1.9317 2.4419 
10 91.38 8.62 0.93551 3.1623 1 1.9609 2.0504 
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Fig. 28: Zero order release kinetics 
 
 
Fig. 29: First order release kinetics 
 
 
Fig. 30: Higuchi Diffusion Kinetics  
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Fig. 31: Korsmeyer Peppas Equation  
 
 
Fig. 32: Hixson Crowell cube root equation 
 
Determination of drug release mechanism of optimized bilayer tablets 
 The order of release was found to be first order, in which R2 value was close to 
1.84  
 The n value of Korsmeyer Peppas equation was found to be 0.574. The release 
followed anomalous (Non-Fickian) transport.84 
 Swelling hydration of the polymer matrix, dissolution of the drug in the polymer 
matrix, diffusion of the drug through the polymer matrix and surface erosion of 
the matrix also play a role in the drug release. The results showed that the 
formulation followed first order release. 
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Stability Study 
                The optimized bilayer tablets were subjected to stability studies and the 
results are given in Tables 40 and 41. 
 
Table 40: Stability study of physical parameters of the optimized formulation 
Parameters Initial 1st month 2nd month 3rd month 
Uniformity of weight (g)* 1.0814 ± 
0.0046 
1.0828 ± 
0.0040 
1.0828 ± 
0.0026 
1.0814 ± 
0.0029 
Thickness (mm)** 6.60 ± 
0.0055 
6.60 ± 
0.0055 
6.60 ± 
0.0055 
6.60 ± 
0.0055 
Hardness (kg/cm2) ** 7.0 ± 
0.0447 
7.0 ± 
0.0447 
7.0 ± 
0.0447 
7.0 ± 
0.0447 
Friability (%) *** 0.14 ± 
0.02 
0.12 ±  
0.04 
0.19 ±  
0.0930 
0.19 ± 
0.0930 
* Mean ± S.D (n=20), ** Mean ± S.D (n=5), *** Mean ± S.D (n=3) 
 
 
Table 41: Assay and Dissolution profile of Bilayer tablets 
Time interval 
(month) 
Drug content (%) * Cumulative %  drug release * 
Losartan 
potassium 
Metformin 
hydrochloride 
Losartan 
potassium  
(at the end of 
30 min) 
Metformin 
hydrochloride 
 (at the end of 
10 hours) 
Initial  97.36 ± 0.1400 95.29 ± 0.2700 98.74 ± 0.1800 91.38 ± 0.1200 
1st month 98.20 ± 0.3000 95.35 ± 0.2500 98.82 ± 0.3200 91.17 ± 0.1900 
2nd  month 98.98 ± 0.2910 95.33 ± 0.2314 98.78 ± 0.3102 91.40 ± 0.1741 
3rd  month 99.46 ±0.3024 95.32± 0.2412 98.82 ± 0.3309 91.33 ± 0.1725 
* Mean ± S.D (n=3) 
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9. SUMMARY AND CONCLUSION 
                      The present study was aimed to develop bilayer tablets of Losartan 
potassium as IR layer and Metformin hydrochloride as SR layer to treat hypertension in 
type II diabetic patients. Hypertension is also one of the complications of type II Diabetes. 
The bilayer tablets were formulated to reduce the polytherapy to monotherapy, thus 
improving patient compliance. The tablets were formulated using hydrophilic polymers 
such as HPMC K4M and HPMC K100M in varying ratios to retard the drug release for a 
period of 10 hours. The immediate release layer of Losartan Potassium was formulated 
using Sodium Starch Glycolate (2% and 4%).  
All the formulations were evaluated for physical characteristics, drug content, dissolution, 
release kinetics and stability studies. 
 The Drug- excipient interaction was investigated with FTIR spectroscopy. The 
study indicated that there was no interaction between the drugs and the excipients 
used in the formulations. 
 The tablets were formulated by wet granulation technique because of the poor flow 
property of the drugs and blends. 
 The formulated granules were evaluated for precompression studies which showed 
that the flow property was good. 
 The formulated tablets were found to be within the limits with respect to 
uniformity of weight, hardness, thickness, diameter and friability. 
 The disintegration time of IR tablets containing SSG 4% was found to be 
optimum. 
 The drug content of the formulated IR tablets and SR tablets was found to be 
within the limits. 
 Based on in vitro dissolution studies, formulations L2 was optimized and selected 
for final bilayer tablets. 
  Five batches of SR formulations containing varying proportions of HPMC K4M 
and HPMC K100M were subjected to in vitro dissolution study. The formulation 
F5 met the IP specifications at the end of 1st hour, 3rd hour and the 10th hour. Thus 
the formulation F5 was optimized and selected for bilayer tablets. 
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 The optimized formulations of both IR and SR tablets were compressed into 
bilayer tablets. 
 The drug content of the bilayer tablets were estimated by simultaneous estimation 
method and it was found to be within the Pharmacopoeial limits. 
 The in vitro dissolution study of the optimized bilayer tablets containing HPMC 
K4M and HPMC K100M in the 1:1 ratio retarded the release and met the IP 
specifications. 
 The release kinetics of the optimized tablets showed that it follows first order 
release kinetics. The release of the drug from the matrix layer was depending on 
diffusion, swelling and erosion of the polymer. 
 The stability studies indicated that the bilayer tablets were stable and do not show 
any significant changes in the physical characteristics, drug content and 
dissolution. The results obtained were found to be within the limits.  
 
Future scope 
 The in vivo studies have to be conducted and in vitro - in vivo correlation has to be 
done. 
 Clinical studies could be carried out in healthy volunteers and Biopharmaceutical 
data has to be evaluated. 
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